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Abstract 
 
G-protein-coupled receptors (GPCR) are transmembrane proteins that play a 
crucial role in the communication of cells with their external environment. In the last 
few years, several GPCR crystal structures have been solved using genetically 
engineered protein. The turkey β1-adrenergic receptor, the human neutrotensin 1 
receptor and the adenosine A2A receptor (A2AR) structures involved the introduction 
of stabilizing mutations. The engineered mutant can be stabilized in an agonist or an 
antagonist bound conformation making the GPCR less flexible and therefore easier to 
crystallize. The aim of this study was to use functional characterization of the key 
thermostabilising mutants of the A2AR in order to understand the molecular basis of 
the thermostabilisation. The different mutants were characterized using a yeast-based 
growth assay, which measures down-stream signaling in response to agonist and 
radioligand binding analysis using both an agonist and an antagonist. Point mutations 
leading to a reduction/loss of constitutive receptor activity have been identified. In 
addition, a single point mutation abolishing the ability of receptor to bind the agonist 
NECA has also been identified. Conformational stabilization of the receptor is thus 
achieved by reducing basal activity along with modifying the ligand-binding pocket 
leading to inability to bind agonist. Such markers can be used to screen for stable 
mutants for structural characterization. Since thermostabilising mutations are not 
directly transferable across receptors, the yeast based growth assay could serve as a 
quick and inexpensive way to screen for mutations for a wide range of GPCRs. 
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1.1 Overview 
 
The plasma membrane plays a major role in maintaining cell integrity by 
separating the inside of the cell from its external environment. However, it is essential 
for the cell to be able to respond to changes in the extracellular environment. This is 
done through the action of integral membrane proteins, which span the phospholipid 
bilayer composing the plasma membrane. These receptors mediate the cellular 
responses to a range of bioactive molecules such as hormones, neurotransmitters and 
a large number of drugs.  
1.1.1 G-protein coupled receptors 
 
G-protein coupled receptors (GPCRs) form the largest family of integral 
membrane protein with ~800 members (Gloriam et al., 2007). Various external 
stimuli such as light, odorants, amino acids, nucleotides, nucleosides, 
neurotransmitters, hormones or peptides can interact with the extracellular side of the 
GPCRs and this triggers a conformational change of the receptor, allowing binding 
and activation of an intracellular heterotrimeric G protein. Once activated by the 
receptor, this G protein is able to interact with secondary effectors to induce a cellular 
response (Howard et al., 2001). It is estimated that between 30 and 50 % of all 
modern drugs and 25 % of the top 100 best selling drugs target GPCRs (Hopkins & 
Groom, 2002; Klabunde & Hessler, 2002). Their importance in terms of cellular 
function and as potential drug targets means that they have been subject to intense 
study. 
GPCRs have previously been classified into five families based on their 
sequence homology and structural similarities. The first one is the rhodopsin family or 
 17 
family A and is by far the largest family with a total of 701 members including 241 
non-olfactory receptors. The second one is the secretin family or family B, which 
comprises 15 receptors. The glutamate family also known as family C is composed of 
15 receptors. Finally, the adhesion and Frizzled/Taste2 families comprise 24 receptors 
each (Fredriksson et al., 2003).  
1.1.2 Structural characteristics of GPCRs 
 
All GPCRs share a very similar basic structure comprising seven 
transmembrane α-helices (7TM) separated by alternating intracellular and 
extracellular loop regions, an extracellular N-terminus and an intracellular C-terminus 
(Fredriksson, 2005). In addition to these common transmembrane domains, each 
family has its own characteristics. The receptors belonging to the rhodopsin subfamily 
share several features; a single conserved cysteine residue in the first two extracellular 
loops, three conserved residues known as the E/DRY motif located on helix III 
(Howard et al., 2001), the CWxPFF motif in the top region of helix VI (Shi & Javitch, 
2002) and the NPxxY motif on helix VII (van Rhee & Jacobson, 1996). All these 
conserved features are believed to be involved in receptor stability or activation.  
The receptors from the family B bind large peptides and their large N termini 
(~150-180 amino-acids) contain three conserved cysteine bridges (Wheatley et al., 
2012). Furthermore, the structures of N termini of several Family B receptors in 
complex with their cognates ligand from different family B receptors allowed the 
identification of a common fold known as “the secretin family recognition fold” 
(Parthier et al., 2009) believed to be crucial for ligand recognition and binding.  
The metabotropic glutamate receptors of family C also have large N termini 
(280 to 580 amino acids), containing the ligand recognition site. The N termini of the 
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receptors of the adhesion family can vary between 200 to 2800 amino acids in length 
and are usually rich in glycosylation sites and contain motifs believed to be involved 
in cell adhesion (McKnight & Gordon, 1998; Stacey et al., 2000). 
The Frizzled/Taste2 family comprises two different groups of receptors. The 
main difference between the two groups is their N terminus, which is small and 
unlikely to contain a ligand recognition domain in the Taste2 receptor while it is 
much longer in the frizzled receptors. However, these two groups share several 
features such as an IFL motif in helix II, an SFLL motif in helix V and an SxKTL 
motif in helix VII (Fredriksson et al., 2003). 
However, the overall sequence homology between GPCRs is low particularly 
in the extracellular loop regions, most likely as a result of the requirement for 
recognition and binding of a wide range of ligands (Peeters et al., 2010). GPCRs 
exhibit significant conformational flexibility reflecting a number of functional states 
(Kobilka & Deupi, 2007). Agonists cause full activation of the receptor whereas 
partial agonists induce submaximal activation of the G protein even at saturating 
concentrations. In addition, it is well documented that many GPCRs exhibit 
constitutive, agonist-independent activity, activating their cognate G proteins in the 
absence of agonist (Milligan et al., 1995; Strange, 2002). Antagonists inhibit ligand 
binding but do not affect constitutive activity, while inverse agonists decrease 
constitutive activity (Fig 1-1). This range of efficacies shows the complexity of the 
activation mechanism of GPCRs. These receptors were usually considered as 
switching between two states, active and inactive but now there is growing evidence 
to suggest multiple active and inactive states (Kahsai et al., 2011; Riitano et al., 1997; 
Rosenbaum et al., 2009; Scaramellini & Leff, 1998). The wide range of 
conformations adopted by the GPCRs make them particularly flexible and unstable 
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proteins (Fredriksson et al., 2003). 
 
Figure 1-1 The level of GPCR activation in the presence of different ligands. Many GPCRs have been 
reported to be constitutively active and hence show a basal level of activation (black line) even in the 
absence of ligands. Full activation of the receptor is achieved with full agonists (red line), whereas 
partial agonists are only able to partially activate the receptor (blue line). Inverse agonists (green line) 
are able to inhibit the basal level of activation of receptor. An antagonist (black line) binds to the 
receptor and inhibits an agonist from activating the receptor however it has no effect on the constitutive 
activity of the GPCR. 
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1.2 GPCR activation and signalling pathways 
 
1.2.1 Ligand binding models 
 
The interactions between the receptor, a G protein and an agonist have been 
described by the “Ternary complex model” (De Lean et al., 1980). Historically, this 
model was developed to account for the unique properties of agonist binding to the 
frog erythrocyte β-adrenergic receptor, which included low affinity and high affinity 
states. De Lean and co-workers explained these experimental data by the intervention 
of a third component: a G protein (Fig 1-2). The binding of the G protein to the 
receptor increases the affinity of the agonist for the receptor accounting for the high 
affinity state observed, while the low affinity state is when the agonist binds to the 
receptor unbound to the G protein. 
  
Figure 1-2 The ternary complex model described the high and low affinity states of the receptor by 
introducing a third component: the G protein. The high affinity state corresponds to the receptor bound 
to the G protein while the low affinity state corresponds to the unbound receptor. The equilibrium 
constant J defines binding of agonist to the receptor while the constant K defines the binding of GPCR 
to G-protein. The β constant defines the differential affinity of the compound to bind to the active 
versus the inactive form of the GPCR (De Lean et al., 1980). 
 
This model was later expanded to the so-called “extended ternary complex 
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model” (Samama et al., 1993). In this model (Fig 1-3), there is an equilibrium 
between an inactive R state and an active R* state. An agonist would stabilize the 
receptor in its active R* state, an antagonist has no influence on the equilibrium while 
an inverse agonist stabilizes the receptor in its inactive R conformation. According to 
this model only the R* state of the receptor is able to bind to the G protein and 
triggers the physiological response. This model explains the constitutive activity 
observed for some GPCRs by assuming the transition between the inactive R to active 
state R* carries a sufficiently low energetic cost that it is possible for some receptors 
to be in the R* state even in the absence of ligand. 
 
Figure 1-3 The extended ternary complex model describes the different states of the receptor and its 
interaction with an agonist (A) and a G protein (G). The receptor undergoes a conformational change 
from R to R* defined by the constant J. The effect of agonist binding is defined by the constant α and 
the effect of G protein binding is defined by the constant M. (Samama et al., 1993) 
 
The extended ternary complex model also suggests that the G protein is only 
able to bind the active R* state of the receptor. However recent evidence shows that 
the M3 muscarinic acetycholine receptor forms an inactive-state complex with Gq 
protein in intact cells (Qin et al., 2011). This inactive-state complex is thought to 
increase the rate of G protein activation and differs from the active-state complex. 
However, there is also evidence for a “collision coupling” model for the α2-
adrenergic receptor (Hein et al., 2005). Using FRET experiments, the authors showed 
that the receptor and the G protein interact only upon agonist binding and that there is 
no pre-assembly of the α2-adrenergic receptor with its G protein. This means that the 
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pre-assembly of a G protein with its GPCR could be a receptor specific event. These 
results strengthen the idea of a more complete model, the so-called cubic ternary 
complex (Fig 1-4). In this model the G protein can bind both the inactive and active 
states of the receptor (Weiss et al., 1996). 
 
Figure 1-4 The cubic ternary complex model describes the different states (active R* state and inactive 
R state) of the receptor and its interaction with the agonist (A) and the G protein (G). In this model the 
inactive R state of the receptor is able to interact with the G protein forming an inactive complex.  
(Weiss et al., 1996) 
 
1.2.2 G protein activation and signalling pathways 
 
1.2.2.1 G protein overview 
 
Heterotrimeric G proteins are the molecular intermediates within the cells 
that switch on specific signalling cascades upon GPCR activation. Heterotrimeric G 
proteins are part of the large family of GTPases and they comprise three subunits: α, 
β and γ. There are 16 genes encoding for Gα subunits, 5 genes encoding for Gβ 
subunits and 12 genes encoding for Gγ subunits, forming over 20 different G proteins 
(Downes & Gautam, 1999). They are divided into four subfamilies according to their 
α subunits: Gαs, Gαi, Gαq and Gα12 (Hepler & Gilman, 1992). In their inactive form, 
G proteins bind GDP tightly through their α subunits. Once a GPCR has been 
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activated, a conformational change within its transmembrane domains allows it to 
interact with its G protein; binding to the receptor triggers a conformational change 
within the G protein resulting in the exchange of GDP for GTP. In turn, this exchange 
causes the dissociation of the α subunit from the βγ dimer. Both the α subunit and the 
βγ complex are then free to interact with effector proteins to propagate the signal and 
trigger a physiological response within the cell. The type of effector protein and the 
response are dependent on the G protein activated. The specific roles of the different 
Gα subunits are unclear but as a rule of thumb, Gαs activates adenylate cyclase while 
Gαi inhibits adenylate cyclase. Therefore Gαs and Gαi regulate the level of cyclic 
AMP (cAMP) within the cell. Gαq activates phospholipase Cβ, which hydrolyses 
phosphatidylinositol 4,5 bisphosphate (PIP2). Hydrolysis of PIP2 results in the 
formation of two important second messengers namely inositol trisphosphate (IP3) 
and diacylglycerol. IP3 activates calcium channels leading to release of Ca2+ from 
intracellular stores into the cytosol (Bockaert & Pin, 1999) while diacylglycerol 
activates protein kinase C. Gα12 activates Rho guanine nucleotide exchange factors 
(GEFs) (Simon et al., 1991). The βγ subunit has been shown to interact with 
Phospholipase A and C, ion channels and kinases (Milligan & Kostenis, 2006).  
The autocatalytic activity of the α subunit then hydrolyses the GTP back to 
GDP allowing the heterotrimer to reform and end the signalling cascade (Fig 1-5). 
The duration of the signal depends on the rate of GTP hydrolysis by the autocatalytic 
α subunit (Cabrera-Vera et al., 2003). 
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Figure 1-5 Schematic of the activation steps of a GPCR: 1 Agonist binds to the receptor. 2 
Recruitment of the G protein on the intracellular side of the GPCR. 3 GDP/GTP exchange. 4. G protein 
dissociation and activation of effector proteins. 5 Hydrolysis of GTP to GDP.  
 
1.2.2.2 The Gα  subunit structure 
 
The Gα subunit comprises two domains: a GTPase domain involved in 
binding and hydrolysing GTP and a helical domain, which binds the GTP to a site 
within the core of the G protein. The GTPase domain comprises a six-stranded β-
sheet surrounded by five α-helices (Fig 1-6). The most conserved regions of this 
domain are the five loops containing the diphosphate-binding (P-) loop (GxGESGKS), 
the Mg2+-binding domain (RxxTxGI and DxxG) and the guanine ring binding motifs 
(NKxD and TCAT). All α-subunits contain a post-translational lipid modification at 
the N terminus responsible for the membrane localisation of the α subunit (Chen & 
Manning, 2001; Smotrys & Linder, 2004). 
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Figure 1-6 Structure of the Gαi subunit bound to GDP, showing the GTPase domain containing the 
conserved regions within the loops in magentas and the helical domain burying the GDP within the 
core of the protein (pdb access code: 1GG2) 
 
 The GTPase domain also contains three flexible loops near the c-phosphate 
binding site, named Switches I, II and III (Oldham & Hamm, 2006). Switch II is of 
particular interest as it plays a crucial role in the binding of effector proteins. When 
the GDP bound α subunit is in complex with the βγ dimer, the switch II forms a loop 
that is buried within the heterotrimer (Fig 1-7A). In contrast, in the active GTP bound 
state, the γ-phosphate stabilizes the α-helix formed by switch II, which then becomes 
available for interaction upon dissociation of the α subunit from the βγ complex (Fig 
1-7B). The importance of this switch II α-helix for interaction with effector protein 
has been confirmed by the high-resolution structure of the GαS domain in complex 
with the catalytic domain of the mammalian adenylate cyclase (Tesmer et al., 1997) 
(Fig 1-7C). Upon hydrolysis of GTP to GDP, the helix formed by the switch II is no 
longer stabilised and becomes disordered (Fig 1-7D). 
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Figure 1-7 Crystal structure of a Gα subunit bound to (A) GDP and in complex the βγ subunits (pdb 
access code: 1GG2), (B) bound to GTPγS (pdb access code: 1AZT), (C) bound GTP and interacting 
with the catalytic domain of the adenylate cyclase (pdb access code: 1AZS) and (D) bound to GDP in 
its deactivated form (pdb access code: 1GDD). In each case, the switch II is shown in red. 
 
1.2.2.3 The Gβγ  subunit structure 
 
The β subunit structure is a seven-bladed β-propeller structure with seven 
WD-40 repeats. Each blade comprises four anti-parallel β-strands and the N terminus 
forms an α-helix that interacts with the N terminus of the γ subunit through a coiled 
coil interaction, while the C terminus of the γ subunit interacts with the core of the β 
subunit (Garritsen et al., 1993) (Fig 1-8). The γ subunit is composed of two helices 
connected by a loop. Together with the β subunit they form a complex that does not 
dissociate except by denaturation. The γ subunit undergoes post-translational lipid 
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modifications, which allow the protein to associate with the membrane (Fukada & 
Kokame, 1994). 
 
Figure 1-8 Structure of the βγ subunit of the Gi (pdb access code: 1GG2). The β subunit in green forms 
a seven-bladed β-propeller structure. The γ subunit in blue comprises two helices connected by a loop 
 
1.2.2.4 Receptor/G protein interaction 
 
The recent structure of the β2 adrenergic receptor (β2AR) in complex with 
the Gs protein has provided unprecedented details of G protein/GPCR interaction 
(Rasmussen et al., 2011a). However, prior to that a number of different studies had 
highlighted a number of key regions of the G protein important for receptor/G protein 
interaction and specificity. The C terminus of the α subunit has been shown to play a 
crucial role in receptor/G protein interaction (Bourne, 1997; Conklin & Bourne, 1993; 
Martin et al., 1996; Wess, 1997). For example, an 11-amino acid peptide 
corresponding to the C terminus of the αt subunit is able to bind the activated 
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rhodopsin receptor and to compete with the Gt heterotrimer (Aris et al., 2001; Hamm 
et al., 1988). In addition, pertussis toxin uncouples the Gi protein from its GPCR by 
catalyzing the ADP ribosylation of a Cys residue located on the C-terminus of the Gαi 
subunit (Van Dop et al., 1984; West et al., 1985). Moreover, several reports of 
mutations in this region of the G protein affecting the receptor-G protein specificity 
have been published (Conklin et al., 1996; Osawa & Weiss, 1995; Sullivan et al., 
1987). Although, the last 11 amino acids of the C terminus of the α subunit play a 
critical role, there are other regions of the G protein involved in receptor-G protein 
interactions. Indeed, within the last 11 amino acids of the C terminus of αt and αi, 
only one is different, yet the 5HT1B serotonin receptor selectively activates Gi. Other 
critical regions for receptor coupling specificity have been identified within the N 
terminus region of the α subunit (Kostenis et al., 1997) as well as several loops (Bae 
et al., 1999; Cai et al., 2001; Onrust et al., 1997). There is also evidence that the βγ 
subunits play a role in receptor binding either directly or indirectly through 
stabilization of the α subunit (Ford et al., 1998).  
As mentioned earlier, a crystal structure of the β2AR in complex with a Gs 
protein has now been solved. This high-resolution structure shows details of the 
interaction between the receptor and the C terminus of the α subunit. The large 
movement of helices V and VI away from the core of the receptor allows the α 
subunit C terminus to penetrate within the transmembrane domain of the receptor 
where it forms primarily non-polar interactions except for the packing of Tyr391 of 
the G protein against Arg131 of the highly conserved DRY motif (Rasmussen et al., 
2011a). There is also an extensive polar interaction network between the C terminus 
of the α subunit and the intracellular ends of helices III and V (Fig 1-9). The crystal 
structure also shows interaction between the N terminus of the α subunit and the ICL2 
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of the receptor. Interestingly, when comparing the structure of the α subunit in 
complex with the β2AR (pdb access code: 3SN6) with the structure of the α subunit 
bound to GTPγS (pdb access code: 1AZT), the main difference is a large rotation of 
the helical domain relative to the GTPase domain leaving the nucleotide-binding site 
open (Rasmussen et al., 2011a). 
 
Figure 1-9 Crystal structure of the β2AR (cyan) in complex with GS (green) showing the polar 
interaction network between the C terminal tail of the Gαs subunit and the intracellular ends of helices 
H III and H V (pdb access code: 3SN6) (Adapted from Rasmussen et al, 2011) 
 
1.2.3 Other processes in the GPCR activation cycle 
 
In addition to G protein activation, there are other essential processes in the 
GPCR activation cycle such as desensitization, internalization, degradation and 
resensitization. The desensitization of the receptor is essential to protect the cell from 
over-stimulation of the receptor and is achieved at different levels of the activation 
pathway (Luttrell & Gesty-Palmer, 2010). For instance, G protein signalling is 
terminated through the GTPase activity of the regulators of G protein signalling 
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(RGS) family of proteins (Ross & Wilkie, 2000). These proteins enhance the intrinsic 
GTPase activity of the Gα subunit and therefore accelerate the reformation of the 
inactive G protein heterotrimeric complex. The most important desensitization 
mechanisms happen through receptor phophorylation, either by second-messenger 
dependent kinases (cAMP-dependent protein kinase (PKA) and protein kinase C 
(PKC)) or by G protein-coupled receptor kinases (GRK). PKA and PKC are activated 
by increasing concentrations of second messengers such as cAMP, Ca2+ and 
diacyglycerol, due to GPCR activation (Ferguson, 2001). Phophorylation of the 
receptor at the ICL3 or at the C-terminal tail by PKA and PKC decreases receptor/G 
protein coupling. This desensitization is called “heterologous” desensitization because 
it is independent of ligand binding. In contrast, “homologous” desensitization only 
occurs on activated receptors. GRKs only phophorylate activated receptors on serine 
and threonine residues within ICL3 and the C-terminal tail of the receptor. 
Phophorylation by GRKs of the receptor triggers translocation of arrestins from the 
cytosol to the plasma membrane where they bind to the intracellular part of the 
receptor, preventing G protein binding (Stoffel et al., 1997). The recent high 
resolution structure of active β-arrestin 1 in complex with a V2 vasopressin-receptor-
derived phosphopeptide shows detailed interactions between the phosphates of the 
peptide and arginine and lysine residues on the β-arrestin, highlighting the role of 
phosphorylation in β-arrestin binding (Shukla et al., 2013). 
Binding of arrestin to the receptor upon phophorylation by GRKs triggers 
another key event in GPCR regulation: internalization via clathrin-coated vesicles 
(Fig 1-10). There are seven GRKs and four arrestins. Two GRKs and two arrestins 
(arrestin 1 and 4) are expressed exclusively in the retina. The other GRKs and 
arrestins (arrestin 2 or β-arrestin 1 and arrestin 3 or β-arrestin 2) are ubiquitously 
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expressed. Upon binding to a phophorylated receptor, the β-arrestins are able to bind 
to the heavy chain of clathrin and to the β2 adaptin subunit of the AP-2 complex 
(Goodman et al., 1996; Krupnick et al., 1997; Laporte et al., 2000; Laporte et al., 
1999). Upon formation of this complex, the receptor is then clustered in clathrin-
coated pits, which are pinched of the cell surface by the motor protein, dynamin 
(Pierce et al., 2002) (Fig 1-10). Once a receptor has been internalized, it is either 
rapidly recycled, targeted to endosomes and then slowly recycled or targeted to 
lysosomes for degradation. The rate of receptor recycling, or resensitization, is 
dependent on receptor subtypes. One class of GPCR, class A, forms transient 
complexes with arrestins that dissociate shortly after internalization at or near the 
cellular surface (Anborgh et al., 2000; Oakley et al., 2000). These receptors, 
including the β2AR, tend to resensitize rapidly. In contrast, members of family B, 
form tighter complexes with arrestins and are targeted to larger endosomes enriched 
in a GPCR-specific phosphatase activity (Ferguson, 2001; Oakley et al., 2000). These 
receptors are slowly recycled back to the plasma membrane. Finally, some GPCRs are 
not resensitized at all, but exclusively targeted to lysosomes where they are degraded 
(Bremnes et al., 2000; Trejo & Coughlin, 1999). Several studies have shown that the 
C-terminal tail of the receptor plays a key role in the intracellular sorting of GPCRs 
(Anborgh et al., 2000; Trejo & Coughlin, 1999; Zhang et al., 1999). 
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Figure 1-10 GPCR desensitization, degradation and resensitization mechanisms. Upon activation by an 
agonist, the receptor is phosphorylated on its ICL3 and C-terminal tail. Once phophorylated, the 
receptor forms a complex with β-arrestin, which triggers internalization via clathrin coated vesicles. 
Once internalized, the receptor is either recycled back to the plasma membrane or targeted to 
lysosomes for degradation. 
 
In addition to preventing G protein coupling and triggering receptor 
internalization, arrestins are also able to attenuate G-protein-dependent signalling by 
recruiting enzymes that degrade second messenger (Luttrell & Gesty-Palmer, 2010). 
For instance, the β2AR forms a complex with β-arrestin 2 and with a cAMP 
phosphodiesterase, increasing the rate of cAMP degradation (Perry et al., 2002). 
Similarly, the diacylglycerol produced upon activation of the muscarinic M1 receptor 
is degraded to phosphatidic acid by diacylglycerol kinase recruited by arrestin 
(Nelson et al., 2007) 
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1.3 Biased agonism and multiple active 
conformations 
 
1.3.1 G protein independent signalling 
 
It was originally thought that GPCRs signalled exclusively through G 
proteins and that β-arrestins were only responsible for receptor desensitization and 
internalization. However, it has now become evident that GPCRs are also able to 
signal in a G-protein-independent manner through β-arrestins. Several reports have 
shown that β-arrestins are involved in kinase activation (DeWire et al., 2007), 
transcriptional control (Ma & Pei, 2007) and transactivation (Buchanan et al., 2006). 
The first example of GPCR signalling through a β-arrestin-dependent 
pathway was the recruitment of activated SRC, a tyrosine kinase, that led to the 
activation of extracellular signal-regulated kinase (ERK) (DeFea et al., 2000a; 
Luttrell et al., 1999). It was demonstrated that β-arrestins are able to scaffold specific 
components of the mitogen-activated protein kinase (MAPK) cascade. For instance, 
an agonist-induced β-arrestin 2, Raf-1, MEK1, and ERK1/2 signaling complex was 
described upon activation of the Angiotensin 1A receptor (AT1AR) (Luttrell et al., 
2001). Furthermore, stimulation of the protease-activated receptor 2 (PAR2) resulted 
in the formation of a complex involving the activated receptor, β-arrestin 1, Raf-1 and 
phosphorylated ERK (DeFea et al., 2000b). Interestingly, ERK activation by β-
arrestins seems to have different physiological consequences compared to ERK 
activation by G protein. Indeed, ERK activated by G protein triggers stimulation of 
transcription factors such as ELK1 in the nucleus (Tohgo et al., 2002) while ERK 
activated by β-arrestins are retained in endocytic vesicles (Luttrell et al., 2001) and 
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seems to have effects on chemotaxis and cytoskeletal rearrangements (Barnes et al., 
2005; Ge et al., 2003). Not only are the effects of the two ERK pathways spatially 
distinct but they are also temporally distinct. Indeed, G-protein-activation of 
phosphorylated ERK reaches its maximum after 2 minutes while β-arrestin-activation 
of phosphorylated ERK is maximal after 30 minutes (Ahn et al., 2004; Rajagopal et 
al., 2010). In addition to ERK, β-arrestins have been involved with other MAPKs 
such as c-Jun N-terminal kinase 3 (JNK3) (McDonald et al., 2000; Miller et al., 2001) 
and p38 (Bruchas et al., 2006; Sun et al., 2002) as well as non-MAPK members 
including PI3K (Povsic et al., 2003) and Akt (Beaulieu et al., 2005). 
Furthermore, β-arrestins have also been shown to interact with transcription 
factors such as NFκB. Both β-arrestin 1 and 2 form complexes with IκBα, a protein 
that binds NFκB preventing its nuclear translocation and therefore regulating its 
activity (Gao et al., 2004; Witherow et al., 2004). In addition, β-arrestin 1 has been 
shown to directly interact in the nucleus with the promoter region of several genes 
such as FOS and p27 following activation of δ-opioid receptor (Kang et al., 2005). 
Finally, β-arrestins have been implicated in transactivation of the epidermal 
growth factor receptor (EGFR). This transactivation of EGFR via β-arrestin occurs 
upon activation of the prostaglandine E4 (EP4) receptor (Buchanan et al., 2006). In a 
similar way, β-arrestins can activate the EGFR upon activation of the β1 adrenergic 
receptor, resulting in the activation of cardioprotective pathways (Noma et al., 2007). 
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1.3.2 Biased agonism 
 
It is clear that GPCRs are able to bind and signal through β-arrestins. In 
addition, there is also evidence that specific GPCR is able to couple to different G 
proteins and activate multiple signalling pathways (Hermans, 2003). For instance, the 
α2-adrenergic receptor has been shown to interact with both Gαs and Gαi (Eason et 
al., 1992). The ability of a ligand to favour one pathway over the others compared 
with the endogenous ligand, is called “biased agonism”. The muscarinic acetylcholine 
M1 receptor provided one of the first examples of biased agonism. Indeed, binding of 
the agonist carbachol resulted in activation of both Gαs and Gαq, whereas only PLC 
activity mediated through Gαq was observed when the agonist pilocarpine was used 
(Fisher et al., 1993; Gurwitz et al., 1994). The physiological consequences of biased 
agonism are not yet fully understood but might have important implications for 
clinical therapies. For instance, although morphine biases the activity of the µ-opioid 
receptor towards G protein activation compared with endogenous enkephalin 
peptides, it still triggers some β-arrestin-dependent pathways (Bohn et al., 1999). β-
arrestin 2 knockout mice do not exhibit the side effects associated with morphine such 
as respiratory depression and constipation (Raehal et al., 2005) whereas the analgesic 
effects are still observed. Therefore, a purely G protein biased agonist should exhibit 
the desired analgesic effects without the side effects. The importance of 
understanding biased agonism is also demonstrated by the D2 dopamine receptor, 
which is involved in mental illness. Effects of antipsychotic drugs were believed to be 
mediated through inhibition of adenylyl cyclase upon activation of Gαi and Gαo 
(Enjalbert & Bockaert, 1983). However, recent studies have demonstrated the 
formation of a protein complex comprising the β-arrestin 2, AKT and protein 
 36 
phosphatase 2 (PP2A) in response to dopamine. This complex is the target of Lithium, 
used to treat mental illness such as bipolar disorder (Beaulieu et al., 2005). Therefore, 
it is crucial to better understand the physiological relevance of each specific pathway 
in order to design drugs with retained efficacy but reduced side effects. 
The ability of a receptor to signal through either the G protein or β-arrestin 
pathways appears to be dependent on receptor conformation induced upon binding 
“biased ligands”, which cause receptors to adopt active conformations preferentially 
signalling through one or the other pathway (Kenakin, 2007). However, more 
intriguingly it seems that receptors can adopt alternative active conformations even 
when binding different ligands with the same downstream effects (Kahsai et al., 
2011). It is becoming increasingly clear that the number of active conformations of 
receptors is far greater than originally thought.  
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1.4 Structure determination of GPCRs 
 
The numerous high-resolution structure determinations of rhodopsin, a non-
typical GPCR with a covalently bound ligand (Li et al., 2004; Nakamichi & Okada, 
2006; Okada et al., 2004; Palczewski, 2000; Salom et al., 2006; Standfuss et al., 
2007) have been use as models for other GPCRs. However, these models have 
limitations and it was therefore necessary to obtain high-resolution structures of other 
GPCRs to further understand the precise molecular basis of receptor-ligand 
interaction and the basis of receptor and G protein activation. The high-resolution 
structure determination of bovine rhodopsin was facilitated by its natural abundance 
in bovine eye and by its intrinsic stability. It took another seven years for researchers 
to determine the structure of another GPCR that of the β2AR expressed in a 
recombinant system (Cherezov et al., 2007). This highlights the difficulties of 
obtaining high-resolution structures of GPCRs due to their highly dynamic nature and 
the challenges associated with overexpression of these proteins. However, in the last 
few years, there have been an astonishing 22 further independent X ray high-
resolution GPCR structures excluding Rhodopsin (overall total of 58 structures in 
different conformations or bound to different ligands). This has been made possible 
by the development of expression systems that produce sufficient quantities of 
functional protein for structural studies and a range of new methodological 
approaches, which stabilize the receptors sufficiently to allow purification and 
crystallization.  
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1.4.1 Expression of GPCRs 
 
1.4.1.1 Escherichia coli 
 
The use of E. coli as expression system offers several advantages such as 
rapid and inexpensive production of proteins. E. coli was used successfully for 
expression and purification of several GPCRs such as the cannabinoid CB2 receptor 
((Yeliseev et al., 2005), the adenosine A2A receptor (A2AR) (Weiss & Grisshammer, 
2002) and the serotonin 5-HT1A receptor (Bertin et al., 1992). Although the lack of 
post-translational modification of E. coli allows the production of a homogenous 
population of protein, it can also lead to the misfolding and impaired trafficking of the 
GPCR. For instance, it has been shown that glycosylation is required for proper 
folding and therefore function of rhodopsin (Kaushal & Khorana, 1994). In addition, 
the lipid composition of E. coli membranes differs from that of eukaryotic cells. Lipid 
compositions of membranes have been shown to be crucial for proper folding and 
function of GPCRs such as the oxytocin and the µ-opioid receptors (Gimpl et al., 
1995; Hasegawa et al., 1987; Lagane et al., 2000). 
However, expression of GPCRs in E. coli can be used for rapid expression 
of a large number of constructs for expression and stability screening (Grisshammer 
et al., 1993). This method was used to develop thermostable mutants of the 
neurotensin receptor 1 (NTS1) (Shibata et al., 2009), the A2AR (Magnani et al., 2008) 
and the turkey β1 adrenergic receptor (β1AR) (Serrano-Vega et al., 2008). 
Furthermore, E. coli has been used to express the CXCR1 chemokine receptor as 
inclusion bodies. The protein was subsequently refolded and its structure determined 
by solid state NMR (Park et al., 2012). 
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1.4.1.2 Yeast systems 
 
In contrast to E. coli, yeasts are able to perform post-translational 
modifications, which makes them a more attractive system for GPCR overexpression. 
In addition, yeasts possess endogenous GPCR and G proteins, which means they 
possess the processing machinery needed for functional expression of GPCRs. 
Furthermore, yeasts have a short generation time and the ability to grow on simple 
media making them easy and inexpensive systems to work with. Expression plasmids, 
which can be maintained in episomal form or integrated into the host genome are 
readily available. These incorporate strong promoters such as GAL1 for S.cerevisiae 
and AOX1 for P.pastoris that drive overexpression where up to 80% of protein 
content can be the target protein (Sarramegna et al., 2003).  
However, the lipid composition of yeast membranes is different from 
mammalian membranes. Indeed, yeast produces ergosterol instead of cholesterol, 
which has been reported to be problematic for the proper folding of the target receptor 
(Lagane et al., 2000). 
The methylotrophic yeast Pichia pastoris was used to produce sufficient 
amount of A2AR and histamine H1 receptor for purification and crystallization. The 
high-resolution structures of both receptors were determined subsequently (Hino et 
al., 2012; Shimamura et al., 2011). To date no GPCR structures have been reported 
using protein from the other popular yeast expression system, Saccharomyces 
cerevisiae, although there are a number of reports of high-level functional expression 
of receptors in this system (O'Malley et al., 2007). 
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1.4.1.3 Baculovirus/insect cell system 
 
Most of the recent GPCRs structures were determined with protein expressed 
in insect cells using the Baculovirus system. The Autographa californica baculovirus 
is able to selectively infect insect cells. The gene of interest is cloned into a plasmid 
between sequences of high homology with the Baculovirus genome. When 
cotransfected with the virus in insect cells, the gene of interest is integrated to the 
virus genome by homologous recombination. The most frequently insect cells used 
are those of Spodoptera frugiperda (Sf9 cell line). Due to their eukaryotic nature, they 
are able to perform post-translational modifications, which can be necessary for 
proper folding of the protein (Kaushal & Khorana, 1994) but can also lead to a 
heterogeneous population of receptor (Reilander et al., 1991). The relatively long 
generation time (up to 24 hours) and the complex media needed for the culture of Sf9 
cells make this system both more expensive and time-consuming than yeast or E. coli. 
However, the strong track record of high-resolution structures obtained from protein 
expressed in insect cells make it the standard expression system for structural studies 
of GPCRs. 
1.4.1.4 Mammalian cells 
 
Mammalians cell lines offer the closest environment to the GPCR native 
tissue and therefore present several advantages. Firstly, they can perform very 
complex post-translational modifications. Secondly, the lipid composition of their 
membranes is similar to that of the native environment of the receptor, which as 
discussed earlier can be critical for membrane protein folding (Lagane et al., 2000). 
Finally, they contain G proteins and secondary effectors, which mean they are 
suitable for functional studies. However, the low yield of protein typically obtained 
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from mammalian cells, though GPCR-dependent, make them less suitable for 
structural work (Sarramegna et al., 2003). Furthermore, generation of a stable cell line 
overexpressing recombinant GPCR is extremely time-consuming. To date, no high-
resolution structure of GPCR has been reported using protein expressed in 
mammalian cells. However they have been extremely useful for biochemical and 
pharmacological characterisation of GPCRs. 
 
1.4.2 Stabilisation of GPCRs for structural studies 
 
1.4.2.1 Fusion protein approach 
 
Researchers have made remarkable progress in structural studies through the 
development of GPCR fusion proteins, where a T4 lysozyme (T4L) replaces the 
conformationally dynamic third intracellular loop (ICL3). Although the ICL3 is 
necessary for GPCR function and interaction with G protein, it has been observed that 
proteolytic cleavage of this domain does not lead to the dissociation of the receptor. 
The two domains linked by ICL3 can even be expressed separately and assembled 
later to form a functional receptor (Kobilka et al., 1988). The dynamic nature of ICL3 
was thought to play a key role in the problems associated with crystallisation and 
structure determination of GPCRs. Replacing ICL3 with a well-ordered and stable 
protein removed a dynamic domain, reduced the movement of the transmembrane 
domains and facilitated the formation of crystal contacts essential for growth of well 
diffracting crystals (Rosenbaum et al., 2007). The T4L fulfilled these criteria. In 
addition, the distance between the N and C termini of T4L is similar to the predicted 
distance between the two helices linked by ICL3, and thus can be introduced without 
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distorting the protein structure. Therefore ICL3 was replaced by the T4L. This 
approach has been successfully used to obtain high-resolution structures of a range of 
different GPCRs in complex with antagonists: β2AR (Cherezov et al., 2007; 
Rosenbaum et al., 2007); human A2AR (Jaakola et al., 2008); human dopamine D3 
receptor (Chien et al., 2010); CXCR4 chemokine receptor (Wu et al., 2010); human 
histamine H1 receptor (Shimamura et al., 2011); δ-opioid receptor (Granier et al., 
2012); human κ-opioid receptor (Wu et al., 2012); µ-opioid receptor (Manglik et al., 
2012); the muscarinic M2 (Haga et al., 2012) and M3 (Kruse et al., 2012) receptors; 
the sphingosine-1-phosphate receptor (Hanson et al., 2012); the protease-activated 
receptor 1 (Zhang et al., 2012) and the corticotropin-releasing factor receptor 
(Hollenstein et al., 2013). In addition, this approach has also been successfully 
applied to the structure determination of two agonist-bound state GPCRs: A2AR (Xu 
et al., 2011) and neurotensin receptor (NTSR1) (White et al., 2012). In each case the 
insertion was essential for obtaining well-diffracting crystals, with the T4L mediating 
the crystal contacts.  
In the case of the β2AR, the presence of the T4L was shown to have little 
effect on the ligand binding properties of the receptor (Rosenbaum et al., 2007). In 
addition, comparison of the structures of the β2AR in complex with an antibody or 
fused to the T4L revealed that the two structures were very similar (Rasmussen et al., 
2007) (Fig 1-11) indicating that the presence of the T4L had not greatly altered the 
structure of the receptor and demonstrating the validity of this approach. 
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Figure 1-11 Superimposition of the β2AR structure fused to T4L (cyan; pdb access code: 2RH1) with 
the β2R structure in complex with a Fab (green; pdb access code: 2R4R) reveals that the two structure 
are very similar. 
 
Although the insertion of the T4L has proven highly successful for the high-
resolution structure determination of a number of GPCRs, it has been shown that this 
approach is not suitable for every GPCR since some receptors exhibit decrease in 
expression or stability when fused to T4L (Chun et al., 2012). Five other potential 
fusion partners were identified by Ray Stevens’ group (Chun et al., 2012). The five 
proteins, a C-terminal fragment of T4L, flavodoxin, xylanase, rubredoxin and a 
thermostabilized cytochrome b562 (named cytochrome b562RIL), were selected based 
on the key criteria of appropriate distance between the N and C-termini (between 6-14 
Å) to allow accommodation between helices V and VI of the fusion partner and 
propensity to crystallise. Fusion proteins of both the β2AR and the A2AR were 
screened for expression, yield of isolated protein, thermostability and their propensity 
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to crystallise. The b562RIL-receptor chimeric proteins were selected for further study 
based on their increased thermostability and their improved ability to diffuse through 
the lipidic cubic phase compared with the other chimeric receptors. Both the β2AR-
b562RIL and A2AR-b562RIL produced crystals that diffracted to a resolution of 2.8 and 
1.7 Å respectively. The A2AR-b562RIL structure was subsequently solved to a 
resolution of 1.8 Å, which revealed the presence of a number of water and lipid 
molecules in the structure and provided insights into the allosteric regulation of the 
receptor by sodium ions (Liu et al., 2012). The b562RIL fusion partner was 
subsequently used to obtain the high-resolution structure of the nociceptin/orphanin 
receptor FQ (Thompson et al., 2012), the 5-HT1B and 5-HT2B serotonin receptors 
(Wacker et al., 2013; Wang et al., 2013a), a member of the Frizzled family, the 
smoothed receptor (Wang et al., 2013b), and a member of the secretin family, the 
glucagon receptor (Siu et al., 2013).  
Although b562RIL gave the best results for the β2AR and the A2AR when 
compared with the other fusion partners and allowed the high-resolution structure 
determination of several GPCRs, Rubredoxin gave better results in term of 
thermostability for the CCR5 chemokine receptor. This allowed the subsequent high-
resolution structure determination of the CCR5 chemokine receptor to a 2.7 Å 
resolution (Tan et al., 2013). 
Whilst most of the fusion proteins have involved replacement of the flexible 
ICL3, it is possible to attach the fusion partner to the N-terminus of the receptor (Zou 
et al., 2012) or to replace the ICL2 {Congreve, 2012 #289} (Fig 1-12C). This 
approach was used for the β2 adrenergic receptor + G protein complex (Rasmussen et 
al., 2011a), the nociceptin/orphanin receptor FQ (Thompson et al., 2012) (Fig 1-12B), 
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the smoothed receptor (Wang et al., 2013b) and the glucagon receptor (Siu et al., 
2013). Thus there is flexibility with the fusions with respect to the attachment point as 
well as the fusion partner that can be used (Fig 1-12). 
 
Figure 1-12 (A) Structure of the β2R with the T4L inserted between helices V and VI (pdb access code 
2RH1, (B) Structure of the Nociceptin/orphanin FQ receptor with b562RIL attached at the N-terminus 
(pdb access code: 4EA3, (C) Structure of the corticotropin-releasing factor receptor with the T4L 
inserted between helices III and IV (pdb access code: 4K5Y) 
 
1.4.2.2 Complex formation with antibody fragments 
 
Although agonist-bound structures have been solved using the fusion partner 
approach, the receptors were either in an inactive state (Warne et al., 2011) or only 
partially active state (Lebon et al., 2011a; Lebon et al., 2011b; Xu et al., 2011). In 
order to obtain a crystal structure of a fully activated receptor a different approach 
was needed. This was achieved using antibody fragments. Protein specific antibody 
fragments bind to the receptor of interest and increase the size of the soluble part of 
the molecule, facilitating crystal formation. In addition, the antibody fragment is not 
only protein specific but also conformation specific. This means that the formation of 
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the protein-antibody complex stabilises the receptor in a specific conformation and 
therefore reduces the conformational flexibility of the protein. The first high-
resolution structure of a non-rhodopsin GPCR, the β2AR was determined in an 
inactive conformation using a Fab (Rasmussen et al., 2007) . The structure was solved 
to approximately 3.4 Å and revealed the first insights into the precise structure of a 
receptor ligand binding site as well as providing some information on the overall 
architecture of the helices and loops. 
Subsequently, Rasmussen and co-workers developed a camelid antibody 
fragment, called a nanobody. The nanobody is a single domain protein engineered 
from heavy chain only camelid antibodies and was raised by injecting the β2AR 
bound to the high affinity, slow off-rate agonist (BI71067) into a llama. The 
nanobody exhibits G-protein-like behaviour and stabilises the active-state of the 
β2AR. The β2AR was subsequently crystallised with the nanobody with and without 
the T4L inserted between helices V and VI. However, only the receptor containing the 
T4L produced a high-resolution structure at 3.5 Å (Rasmussen et al., 2011b). 
Comparison of the active-state structure of the β2AR with the inactive-state structure 
provides details on the conformational change undergone by the receptor upon 
activation (Fig 1-13). 
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Figure 1-13 Comparison of the active-state (cyan, pdb access code: 3POG) and inactive-state 
structures of the β2AR (A) intracellular view of the protein showing the large movement of helix VI (H 
VI) upon activation of the receptor (B) extracellular view of the protein showing that both structures 
are very similar. 
 
A nanobody also contributed to the structure determination of the β2AR-Gs 
protein complex (Rasmussen et al., 2011a). The high affinity agonist, BI71067, was 
used to allow the formation of the β2AR-Gs protein complex. Crystallogenesis was 
improved by replacement of the unstructured N-terminus of the receptor with T4L. 
The α-helical component of the Gαs protein was shown to have a variable position 
relative to the rest of the complex. The addition of the pyrophosphate mimic, 
foscarnet, stabilized the α-helical component of the Gαs subunit without disturbing 
the β2AR-Gs complex. Finally, in order to further stabilise the β2AR-Gαs complex, a 
nanobody, Nb35, which bound to both the Gαs and Gβs subunits was also used. Both 
the nanobody and the T4L were involved in the formation of crystal contacts essential 
for crystal lattice formation. This was the first and so far only structure revealing 
details of the precise molecular interactions between a receptor and a heterotrimeric G 
protein (Fig 1-13).  
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Figure 1-14 High resolution structure of the β2AR (cyan) in complex the Gs protein. The T4L fused to 
the N terminus of the receptor is shown in blue, the α subunit is shown is magenta, the β subunit is 
shown in green, the γ subunit is shown in yellow and the Nb35 nanobody is shown in red. (pdb access 
code 3SN6) 
 
Furthermore, the use of a mouse monoclonal antibody has allowed the 
resolution of the A2AR crystal structure (Hino et al., 2012). The protein, expressed in 
Pichia pastoris with its full length ICL3, is bound to an antagonist and therefore 
locked in an inactive conformation. 
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1.4.2.3 Mutagenesis approach 
 
Finally, another technique, developed by Chris Tate and co-workers, involves 
alanine-scanning mutagenesis coupled with radioligand binding analysis following 
heat treatment of the receptor in order to identify mutants with retained functional 
expression but increased thermostability. The stability of the mutants is tested using 
an agonist and/or an antagonist. This strategy produces mutants stabilized in either an 
agonist conformation or an antagonist conformation, hence reducing the 
conformational instability inherent to GPCRs. This in turn facilitates the formation of 
well-diffracting crystals. This approach has been applied to four receptors to date, the 
turkey β1 adrenergic receptor (β1AR) (Serrano-Vega et al., 2008), the A2AR (Magnani 
et al., 2008), the NTSR1 (Shibata et al., 2009) and the human corticotropin-releasing 
factor receptor type 1 (Hollenstein et al., 2013). In each case combinations of a small 
number of point mutations resulted in a dramatic increase in the Tm of the receptor. 
Mutants obtained are much more stable in small chain detergents than the wild-type 
form.  
More specifically, for the A2AR, each residue of the A2AR-A316 truncated 
receptor, between Pro2 and Ala316 were mutated to an alanine or to a leucine if the 
original residue was an alanine. Each mutant is then expressed in E. coli and 
solubilised in n-Dodecyl-β-D-maltopyranoside (DDM). Thermostable mutants were 
determined by heating the receptors at 30°C for 30 min in the absence of ligand, and 
then a ligand binding assay was performed using either the agonist [3H]NECA or the 
inverse agonist [3H]ZM241385. In these conditions, the WT A2AR had a residual 
activity of 50%. Thermostable mutations were selected on the basis of a residual 
activity greater than 70% and 65% and expression levels greater than 30% and 40% 
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of the WT for agonist and antagonist screening respectively. Iterative rounds of 
mutagenesis combining different thermostabilizing mutants resulted in two receptor 
constructs, Rag23, in an agonist conformation, containing five point mutations and a 
Tm 9°C higher than the WT and Rant21, in an antagonist conformation, containing 
four point mutations and a Tm 17°C higher than the WT. Despite these increases in 
Tm, Rag23 and Rant21 were not considered stable enough for crystallisation and a 
slightly different technique was used to further improve the stability of the receptor. 
Instead of heating the partially purified receptor in the ligand free state, it was heated 
in the presence of either the agonist [3H]NECA or the inverse agonist [3H]ZM241385. 
In the case of the agonist conformation, this process resulted in the identification of 
GL26, which has a Tm of 45°C in n-Decyl-β-D-maltopyranoside (DM) and contains 
four point mutations different from those contained in Rag23 (Lebon et al., 2011a). In 
the case of the antagonist conformation, it resulted in the identification of four 
additional point mutations to form A2AR-Star2, which has a Tm of 47°C in DM. For 
both mutants, an extra mutation (N154A) was added to remove a glycosylation site. 
Using this approach, the thermostabilised turkey β1AR was successfully 
crystallised and a number of high-resolution structures of the receptor in complex 
with a range of ligands or without ligand were solved (Huang et al., 2013; 
Moukhametzianov et al., 2011; Warne et al., 2012; Warne et al., 2011; Warne et al., 
2008). The adenosine A2AR was also crystallised resulting in a range of agonist-bound 
and antagonist-bound structures (Dore et al., 2011; Lebon et al., 2011b). The NTSR1 
was also recently crystallised resulting in an agonist-bound structure (White et al., 
2012). However, in that case, the mutant not only contained six thermostabilising 
mutations but also the T4L inserted between helices V and VI.  
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Figure 1-15 High resolution structures of thermostable mutants (A) the β1AR containing six point 
mutations (magenta) in complex with the partial agonist dobutamine (pdb access code: 2YO1) (B) the 
A2AR in an agonist conformation containing five mutations (blue) and bound to the agonist adenosine 
(pdb access code: 2YDO) 
 
One issue with this method is that while the thermostabilising mutations are 
transferable between highly homologous receptors, eg the β1AR and the β2AR 
(Serrano-Vega & Tate, 2009) it has so far not been possible to transfer mutations 
between more distantly related receptors and thus a complete alanine scan must be 
completed for each receptor. One other issue with this approach is the need for a 
reliable ligand-binding assay. 
However, this method has several advantages over the insertion of the T4L 
between helices V and VI or the use of an antibody fragment. Firstly, the ICL3 is 
intact which means the receptor is still able to interact with its G protein. Since the 
protein is still capable of binding to its G protein, it is therefore possible to use a 
signalling assay to investigate the functional profiles of the engineered protein. 
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Consequently, it is possible to determine the physiological relevance of such 
constructs. That is not the case when the T4L fusion technique is used. Secondly, as 
described earlier, the stabilization of the protein occurs through the insertion of 
several point mutations while when using the T4L technique, stabilization mainly 
occurs by the use of high affinity binding and slow off-rate ligands as demonstrated 
by the structure of the A2AR fused to the T4L (Jaakola et al., 2008; Xu et al., 2011). 
This means that the thermostabilising mutation strategy is more relevant to help drug 
design than the T4L fusion strategy. Indeed, in order to be a useful tool for drug 
design, high-resolution structures need to be obtained with different ligands to fully 
explore the structure/activity relationship (SAR) of a family of small molecules 
(Congreve et al., 2012). That includes ligands with low affinity and fast off-rate. By 
definition this would not be possible with the T4L fusion strategy.  
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1.5 Structural insight 
 
1.5.1 Comparison of crystals structures obtained using 
different approaches 
 
As described in the previous section, in the last few years, technical advances 
have allowed the determination of the high-resolution structures of a number of 
GPCRs bound to a number of ligands. However, all of the high-resolution structures 
obtained were of highly engineered receptors. It is therefore crucial to understand 
what impact these modifications have on the crystal structures. The A2AR provides 
useful information in that regard since its structure bound to the inverse agonist 
ZM241385 has been determined using the three different techniques: the T4-
lysozyme fusion strategy (Jaakola et al., 2008), the thermostabilisation approach 
(Dore et al., 2011) and in complex with a mouse antibody (Hino et al., 2012). 
Comparison of these three structures shows interesting features. Although all the 
critical interactions between the ligand and the receptor seem conserved, the position 
of the phenol group of the antagonist differs according to the structures (Fig 1-16C). 
The overall architecture is maintained across the three structures especially within 
transmembrane domains 1, 2, 3, 4 and 7. The main differences lies in TM5 and 6. 
These transmembrane domains are more ordered and extended in the mutant and 
antibody structures compared with the T4L structure, which is certainly due to the 
replacement of the ICL3 by the T4L (Fig 1-16A). In addition, the fusion of the T4L 
and the antibody seem to have disturbed the ionic lock present in the thermostable 
mutant structure and also present in the inactive state of Rhodopsin (Fig 1-16B). This 
is in accordance with the increased affinity for agonist relative to the WT displayed 
by the T4L receptor fusion protein (Rosenbaum et al., 2007).  
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Figure 1-16 Comparison between the three independent high-resolution structures of the A2AR bound 
to the antagonist ZM241385 (sticks): A2AR fused to the T4-lysozyme (green, PDB 3EML), the 
thermostable A2AR mutant (cyan, PDB 3PWH) and the A2AR in complex with a mouse antibody 
(magenta, PDB 3VG9). (A) Differences between TM5 and TM6. (B) The ionic lock in the Rhodopsin 
structure (grey, PDB access code: 1F88) and in the three independent high-resolution structures of the 
A2AR. The distances shown are between are between R102 from the DRY motif on H III and E228 on 
H VI. (C) Differences in the position of the phenol group of the antagonist in the structures. 
 
However, the mechanism underlying the formation of the ionic lock seems to 
be more complicated than originally thought. For instance, the ionic lock is present in 
the high-resolution structure of the human dopamine D3 receptor despite the insertion 
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of the T4L between helices V and VI. Furthermore, the recent structure of the β1AR 
bound to the antagonist carazolol, showed that the receptor can adopt two inactive 
conformations (Moukhametzianov et al., 2011). In the “bent conformation”, the ionic 
lock is present and in the “straight conformation”, helices III and VI are too far apart 
to allow the formation of the ionic lock (Fig 1-17). Surprisingly, the two structures are 
monomers obtained from a single crystal. A similar observation was made with 
cyanopindolol from two different crystals. 
 
Figure 1-17 Superposition of the “bent” (Cyan) and “straight” (green) conformations of the β1AR 
bound to the antagonist carazolol (pdb access code: 2YCW. In the bent conformation, the cytoplasmic 
end of HVI is bent towards HIII allowing the formation of the ionic lock. In the case of the straight 
conformation, HVI and HIII are too far apart to allow the formation of the ionic lock. 
 
The high-resolution structure of the A2AR was also obtained bound to the 
agonist UK-432097 with the T4L inserted between helices V and VI (Xu et al., 2011) 
and bound to the agonists NECA and adenosine as a thermostable mutant (Lebon et 
al., 2011b). Although, the structures were obtained with an agonist bound, it is 
proposed that the receptor is in an intermediate active conformation rather than the 
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fully active conformation. Again, this allows comparison of the influence of the two 
different techniques on the overall structure of the receptor. Although, the agonist-
bound structures were co-crystallised with different ligands, they are very similar 
especially in the transmembrane regions. However, they show small differences in the 
extracellular region, probably due to the difference in the ligands and the absence of 
density for residues 149-157 (Fig 1-18). 
 
Figure 1-18 Structural alignment of the thermostabilised A2AR mutant bound to the agonist NECA 
(green, PDB 2YDV) with the A2AR-T4-lysozyme fusion protein bound to the agonist UK-432097 
(cyan, PDB 3QAK). 
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1.5.2 The ligand-binding pocket of GPCRs 
 
Crystal structures obtained owing to the technological advances made in the 
recent years have provided unprecedented details on GPCRs. The ligand-binding 
pocket is of particular interest in regard to drug design. A systematic comparison of 
residues involved in ligand binding of all the GPCR structures revealed some 
common features in the binding pockets of the different receptors (Venkatakrishnan et 
al., 2013). The following “topologically equivalent residues” located in helices III, VI 
and VII are involved in ligand binding in almost all the receptors: 3.32, 3.33, 3.36, 
6.48, 6.51, 7.39. Of these residues, two pairs (3.36-6.48 and 6.51-7.39) are in contact 
in most receptors and seem to form “a ligand binding cradle” (Fig 1-19) 
(Venkatakrishnan et al., 2013). Residues from other helices form contacts with 
specific ligands in specific receptors. Interestingly, helix I does not seem to be 
directly involved in ligand binding. 
 
Figure 1-19 Ligand binding cradle of the human κ-opioid receptor (pdB access code: 4DJH). The 
ligand is represented as green sticks and the residues forming the ligand binding cradle as cyan sticks. 
The dashed lines show the interactions between the residues. 
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The work done by Chris Tate’s group on the turkey β1AR provides valuable 
details on the ligand-binding pocket and insight into how small changes into the 
ligand-binding pocket can induce a much larger conformational modification in the 
receptor. In addition, their work provides the platform to compare the different 
binding modes of pharmacologically different ligands since they published the high-
resolution crystal structure of the turkey β1AR in complex with antagonists 
(Moukhametzianov et al., 2011; Warne et al., 2008), full agonists, partial agonists 
(Warne et al., 2011) and biased agonists (Warne et al., 2012).  
Although all the different ligands bind in a similar way, a detailed 
comparison of the structure of the receptor in complex with the full agonist 
carmoterol, the antagonist cyanopindolol, the partial agonist salbutamol and the 
biased agonist bucindolol reveals three significant differences which are the rotamer 
conformation changes of S212 and S215 and the contraction of the binding pocket by 
~1 Å (Warne et al., 2011). It is proposed that the rotamer conformation change of 
S215 upon binding of full agonists disrupts interactions between Helices IV and V 
and thus facilitates the formation of the active state of the receptor (Warne et al., 
2011). Furthermore, the rotamer conformation change of S215 observed upon full 
agonist binding, allows formation of a hydrogen bond between the ligand and the 
receptor (Fig 1-20A), whereas when the receptor is bound to the antagonist 
cyanopindolol, S215 forms a hydrogen bond with T126 (Fig 1-20B). This interaction 
between helices III and V is also present in the structures of the receptor bound to 
partial agonists and to biased agonists (Fig 1-20C and D). The disruption of this 
interaction between helices III and V is probably another factor facilitating the 
formation of the active state of the receptor. In contrast, the rotamer conformation 
change of S212 results in the strengthening of interactions between helices V and VI 
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as demonstrated by the formation of a hydrogen bond between S212 and N310. This 
interaction is formed upon binding of full, partial and biased agonists but not in the 
case of antagonists (Fig 1-20). 
 
Figure 1-20 Interactions between different ligands and the β1AR. (A) The full agonist carmoterol 
interacts with S215 and induces the rotamer conformation change of S212 leading to the interaction 
between S212 and N310 (pdb access code: 2YO2). (B) The antagonist cyanopindolol does not disrupt 
the interaction between helices III and V and does not induce the rotamer conformation change of S212 
(pdb access code: 2VT4). (C) The partial agonist salbutamol does not disrupt the interaction between 
helices III and V but induces the rotamer conformation change of S212 leading to the interaction 
between S212 and N310 (pdb access code: 2YO4). (D) The biased agonist bucindolol does not disrupt 
the interaction between helices III and V but induces the rotamer conformation change of S212 leading 
to the interaction between S212 and N310 (pdb access code: 4AMI). 
 
In addition, the contraction of the ligand binding pocket observed is specific 
to full and partial agonists. It is proposed that this contraction relies on strong 
hydrogen bonds between the catechol (or equivalent) moiety and helices V and VI on 
one hand and between the secondary amine and the β-hydroxyl group in the agonist 
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and the amino acid side chains in helices III and VII on the other hand (Warne et al., 
2011). While this is the case for the full agonists, it is also true, though weaker for the 
partial agonists, which is probably due to a reduced number of hydrogen bonds 
compared with the full agonist. However, this contraction is not observed in the cases 
of the antagonists and biased agonists. This is certainly due to the increased distance 
between the catechol (or equivalent) moiety and the secondary amine within the 
ligands. The two biased agonists co-crystallised with the β1AR have previously been 
shown to be β1AR antagonists but they are able to activate G-protein-independent 
pathways (Warne et al., 2012). It is therefore not surprising that they exhibit at least 
partially similar binding characteristics to the antagonist cyanopindolol. However, 
both biased agonists have aromatic substituents on the secondary amine. These 
substituents are able to make additional interactions with helices 2, 3 and 7 of the 
receptor as well as with extra-cellular loop 2 (Fig 1-21). It is therefore only logical to 
propose that the G-protein-independent signalling properties of these compounds are 
due to these extra interactions since they are unique to the biased agonists (Warne et 
al., 2012). 
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Figure 1-21 Extra interactions between the aromatic substituent of the biased agonist bucindolol and 
the β1AR (pdb access code: 4AMI). The protein is shown in wheat, the ligand in cyan and the residues 
in green. 
 
1.5.3 Structural changes in GPCRs upon activation 
 
Although some of the crystal structures of the β1AR described in the 
previous section were obtained in complex with agonists, the receptor was in an 
inactive, non-signalling conformation formed on initial agonist binding. Despite the 
valuable details these structures provided on the ligand-binding pocket and the ligand 
binding mechanisms, they did not provide any information on the conformational 
changes undergone by the receptor upon activation. However, the high-resolution 
structures of the A2AR bound to agonists, the bovine ligand-free opsin receptor in an 
active conformation and the β2AR in complex with Gs or a nanobody, have provided 
some of the missing information. 
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1.5.3.1 The A2AR structures 
 
Three different structures of the A2AR bound to agonists were obtained. The 
first one was solved in complex with the high affinity slow off-rate agonist UK-
432097 with the T4L inserted between helices V and VI (Xu et al., 2011), the other 
two were obtained from a thermostabilised mutant in an agonist binding conformation 
and in complex with either adenosine or NECA (Lebon et al., 2011b). All three 
structures are very similar and the structure of the A2AR in complex with NECA will 
be used for further discussion in this paragraph. Comparison of the active 
conformation with the structure of the A2AR thermostabilised in an antagonist 
conformation bound to ZM241385 (Dore et al., 2011), reveals three major differences 
in the overall architecture of the receptor. Firstly, the interaction between Thr88 and 
the ribose ring of the agonist, as well as non polar interactions with Val84 and Leu85 
result in a ~2 Å upward movement of helix III along the helical axis (Fig 1-22A). 
Figure 1-22 Superimposition of the structures of the A2AR bound to the agonist NECA (green, pdb 
access code: 2YDV) and bound to the inverse agonist ZM241385 (cyan, pdb access code: 3PWH). (A) 
2 Å upward movement of helix III upon binding of the agonist NECA. (B) Movements of helices V 
and VI upon binding of the agonist NECA viewed from cytoplasmic side.  
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Secondly, the interaction of the agonist with helices III and VII, thought to 
be involved in receptor activation, leads to the inward shift of helix VII and the 
upward movement of helix III resulting in the formation of a bulge in helix V (Lebon 
et al., 2011b). The formation of the bulge is prevented by the binding of the inverse 
agonist ZM241385, demonstrating its importance in the activation mechanism. 
Finally, there is also a modification in the conformation of the intracellular ends of 
helices V, VI and VII (Fig 1-22B). Indeed, there is a 40° rotation and a 3 to 4 Å 
outward tilt of helix VI. As a result, helices V and VI are closer to each other by about 
2 Å in the active conformation. However, it is believed that the receptor bound to 
NECA is not in the fully active conformation. Indeed, the outward movement of helix 
VI observed is not enough to open up the G protein-binding cleft. 
1.5.3.2 The rhodopsin structures 
 
In this regard, the crystal structures of the bovine opsin receptor both alone 
or in complex with a synthetic peptide corresponding to the C-terminus of the Gα, in 
the fully active Ops* conformation provide useful information (Park et al., 2008; 
Scheerer et al., 2008). Comparison of the rhodopsin and the opsin structures reveals 
several key conformational changes upon receptor activation (Hofmann et al., 2009). 
It is worth noting that very few changes are observed in the extracellular end of the 
receptor. Furthermore, helices I to IV form a stable helical bundle that is unchanged 
in the Ops* structure (Fig 1-23). 
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Figure 1-23 Superposition of the opsin (green) and rhodopsin (cyan) structures (pdb access code: 
3CAP and 1F88 respectively) showing the similarity in helices I to IV that form a stable helical bundle. 
Helices V, VI and VII are shown in wheat. 
 
The main conformational modifications are observed in helices V, VI and 
VII. Indeed, the intracellular part of helix VI undergoes an outward movement of 5 to 
6 Å. In addition, helix 5 is extended by 1.5 to 2.5 turns and moves towards helix VI 
by 2 to 3 Å. Consequently, helices V and VI move closer to each other and away from 
the helix bundle, resulting in opening of the G protein-binding cleft as observed in the 
structure of opsin in complex with the Gα peptide (Park et al., 2008). In the Ops* 
structure, the highly conserved DRY and NPxxY motifs form new interactions. 
Helices III and V interact through the formation of a hydrogen bond between Arg135 
and Tyr223 and similarly, helices V and VI interact through the formation of a 
hydrogen bond between Lys231 and Glu247. This means that in this conformation, 
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the “ionic lock” is broken and the new position of helix VI is stabilised through this 
new interaction with helix V. In addition, the conformational change of the 
intracellular end of helix VII results in the rotation of Tyr306, which prevents helix 
VI to move back towards helix III (Fig 1-24). 
 
Figure 1-24 Superposition of the opsin (green) and rhodopsin (cyan) (pdb access code: 3CAP and 
1F88 respectively) showing the large conformational changes of helices V, VI and VII viewed from 
cytoplasmic side. Helix V moves towards helix VI, which moves outward, allowing a hydrogen bond 
formation between K231 and E247. Movement of helix V also allows interaction between Y223 and 
R135, while rotation of Y306 prevents helix VI from moving back towards helix III. 
 
1.5.3.3 The β2AR structures 
 
The most exciting addition to the growing collection of high-resolution 
structures of GPCRs is most certainly the structure obtained by Brian Kobilka’s group 
of the β2AR in the active state in complex with the Gs protein (Rasmussen et al., 
2011a). Although prior to this one, an other structure of the β2AR in an active 
conformation in complex with a nanobody was solved (Rasmussen et al., 2011b), the 
β2AR-Gs complex structure will be used for further discussion in this paragraph. The 
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changes observed in the structure of the β2AR receptor in the active conformation 
compared with the receptor in an inactive conformation bound to the antagonist 
carazolol are very similar to that observed between the Ops* and rhodopsin structures. 
Indeed, the major modification in the β2AR-Gs structure is an outward movement of 
helix VI of 14 Å compared with the β2AR in complex with carazolol (Fig 1-25). In 
addition, as previously observed, the rotation of Tyr326 on the intracellular end of 
helix VII, stops helix VI from moving back towards helix III (Fig 1-25) and the ionic 
lock is broken. However, while the arginine of the DRY motif in the opsin structure 
interacts with helix V, in the case of the β2AR, the arginine interacts with the G 
protein. 
 
Figure 1-25 Superimposition of the structures of β2AR in an inactive conformation bound to the 
inverse agonist carazolol (green, pdb access code: 2RH1) and in an active conformation bound to an 
agonist and in complex with GS (cyan, pdb access code: 3SN6) viewed from cytoplasmic side. 
 
As seen in the A2AR, helix V forms a bulge centred on Ser207, which moves 
towards the binding pocket by 2.1 Å. This leads to the rotation and subsequently to 
the tilt of helix VI. Finally, one key observation is that the active conformation is 
stabilised by extensive interactions with GαRas while there are no direct interactions 
between the receptor and the Gβ or Gγ subunits. 
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1.5.3.4 Molecular signatures 
 
Ventakakrishnan and colleagues performed a systematic comparison of all 
GPCRs structures regardless of their conformation. They identified “a consensus 
network of 24 inter-TM contacts mediated by 36 topologically equivalent amino 
acids” (Venkatakrishnan et al., 2013). Interestingly, helix III seems to play a central 
role in maintaining the helical bundle scaffold as it does in the ligand-binding pocket. 
This is indeed confirmed by mutagenesis studies that demonstrated that in general 
mutation in helix III causes either constitutive activity or receptor inactivation (Han et 
al., 2012; Jiang et al., 1997; Jiang et al., 1996). 
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1.6 The adenosine receptors family 
 
The adenosine receptor family is part of the class A GPCR family and is 
comprised of four proteins, the A1, A2A, A2B and A3 receptors, which all bind the 
endogenous ligand adenosine (Fredholm et al., 2001). These receptors are classified 
based on their affinities for adenosine analogues and their mechanism of signal 
transduction (Klinger et al., 2002a). Both A2AR and A2BR activate adenylyl cyclase 
via Gs resulting in an increase of cyclic AMP levels (Hide et al., 1992). The A1 and 
A3 receptors interact with Gi and Go proteins, leading to inhibition of cAMP 
production (Klinger et al., 2002a). 
The A2AR is highly expressed in the spleen, thymus, leukocytes, blood 
platelets, striatopallidal GABAergic neurons and the olfactory bulb. It is also 
expressed at lower levels in the heart, lung and blood vessels (Fredholm et al., 2001). 
It is therefore not surprising that the A2AR has been linked to a number of various 
diseases such as neurodegeneration (Stevens et al., 2002), Parkinson’s disease 
(Hauser & Schwarzschild, 2005; Volpini et al., 2009; Xu et al., 2005), sleep disorder 
(Satoh et al., 1998), respiratory disorder (Fozard et al., 2002), hypertension 
(Fredholm et al., 2001) and ischaemia (Chen et al., 1999; Gui et al., 2009) among 
others. In addition, the role and function of the A2AR is further complicated by its 
propensity to form heterodimers with other GPCRs. The A2AR has been shown to 
form dimers with the cannabinoid CB1 receptor (Ferre et al., 2009), the glutamate 
mGluR5 receptor (Ferre et al., 2002) and finally the dopamine receptors D2 (Fuxe et 
al., 2005) and D3 (Torvinen et al., 2005), which have important implications in the 
treatment of Parkinson’s disease. This underlines the importance of the adenosine 
receptors as therapeutic targets and the need to obtain selective agonists and 
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antagonists. A large number of pharmaceutical companies have developed or are 
developing A2AR selective agonists or antagonists with various successes. Of these, 
Regadenoson is an FDA approved A2AR selective agonist used in cardiac stress tests, 
Preladenant is a selective A2AR antagonist that showed great results in Parkinson’s 
disease animal model but failed to show efficacy over placebo in phase III clinical 
trials and Tozadenant is a selective A2AR antagonist for the treatment of Parkinson’s 
disease that was discontinued due to toxicology issues (de Lera Ruiz et al., 2013). The 
abundance of publications and patents is proof that the A2AR is still actively 
investigated by pharmaceutical companies. This is one of the reasons why so much 
effort has been invested in the structure determination of A2AR. Five independent 
structures of this GPCR have now been solved: a thermostabilised A2AR mutant 
bound to two different agonists (Lebon et al., 2011b), a thermostabilised A2AR mutant 
bound to a range of antagonists (Dore et al., 2011), the A2AR-T4-lysozyme fusion 
protein bound to an agonist (Xu et al., 2011) and an antagonist (Jaakola et al., 2008) 
and finally the full length A2AR in an inactive complex with a mouse antibody (Hino 
et al., 2012). 
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1.7 Aim of the study 
 
Despite the significant progress made towards structure elucidation of 
GPCRs in the last few years, the mechanisms of ligand recognition and receptor 
activation are still unclear. Although the high-resolution structures of the non-
rhodopsin GPCRs published so far show surprising similarities, it is still necessary to 
obtain further structures. In addition, it is important to understand at a molecular level 
the specificity of each receptor as well as the difference of efficacies of the ligands as 
it becomes clearer that the GPCRs adopt a much greater range of conformations than 
originally described by the classical models of GPCR activation. 
As discussed previously, one way of stabilising a given GPCR is to generate 
thermostable mutants through alanine-scanning mutagenesis coupled with radioligand 
binding analysis. This technique has been used to produce thermostable mutants of 
the A2AR (Magnani et al., 2008). In the present study, three of the most stable 
mutants, at that time, were selected for further functional characterisation, namely 
Rag23, Rant5 and Rant21 (fig 1-26, Table 1-1). Two of these mutants are in a 
preferentially antagonist conformation (Rant5 and Rant21) and the other one in an 
agonist conformation (Rag23). All these receptors contain several point mutations. 
The intermediate mutants between Rant5 and WT as well as between Rag23 and WT 
have also been characterised. 
Table 1-1 Point mutations contained in the different thermostable constructs studied 
Constructs Mutations 
Rag23 F79A, A184L, R199A, L208A, L272A 
Rant5 A54L, T88A, V239A 
Rant21 A54L, T88A, K122A, V239A 
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Figure 1-26 Snake plot of the A2AR showing the position of the mutations for the thermostable mutants 
(Blue: agonist mutations, Red: antagonists mutations) (adapted from Magnami et al. 2008) 
 
The aim of this study was to functionally characterise these mutants using a 
yeast whole cell growth assay in order to further understand how these mutations 
stabilise the receptor and affect its function and also to develop a high throughput and 
inexpensive tool to screen for thermostable mutants for other GPCRs. Indeed the 
functional assay is virtually applicable to any GPCR that can be expressed in yeast 
and has been used successfully with the cannabinoid CB1 and CB2 receptors (Dowell 
& Brown, 2009), GPR41 and GPR43 (Brown et al., 2003), the adenosine A2B receptor 
(Beukers, 2004) and the sphingosine S1P1 receptor. Therefore, if the stabilizing 
effects of the mutant receptors can be linked to function in the yeast growth assay, it 
may be that this method used in combination with either alanine-scanning 
mutagenesis or random mutagenesis methods (Dodevski & Pluckthun, 2011) would 
provide a powerful screening tool for the production of thermostable mutants. 
The results presented here reveal that inhibition of constitutive activity is correlated 
with receptor thermostabilisation. The data also strongly suggest that the agonist-
induced and constitutive active conformations are distinct. In addition, the data 
highlight the role of individual amino acids residues in receptor function. 
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2 Development of the Yeast Functional 
Assay 
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2.1 Introduction 
 
As described previously, most of the crystal structures of GPCRs obtained so 
far are of highly engineered proteins. Although most of these engineered receptors 
have been well characterized in terms of ligand binding, far less is known about their 
signalling profiles. Indeed, replacement of ICL3 by T4L or the presence of an 
antibody at the G protein-binding site has prevented characterization of signalling 
function (Fig 2-1). 
 
Figure 2-1 Structure of the A2AR as a fusion protein with the T4L (A) and in complex with a Fab (B). 
In both cases the presence of partner protein prevents the G protein from interacting with the receptor. 
 
In addition, many of the thermostabilised mutant structures have been 
obtained of receptor preferentially in an antagonist conformation, with reduced 
affinity for agonists, making meaningful functional characterization difficult. 
However, one of the thermostabilised mutants of the A2AR (A2AR-GL31), expressed 
in HEK293 cells (Lebon et al., 2011b) and preferentially in an agonist conformation, 
has been functionally characterized using a cAMP assay. The construct used to 
 74 
determine the crystal structure of the neurotensin receptor (NTSR1-GW5), expressed 
in insect cells, has also been functionally characterized using a GTPγS assay (White et 
al., 2012). However, in both cases, the thermostable mutants were unable to activate 
their cognate G protein upon agonist binding (Lebon et al., 2011b; White et al., 
2012). The deletion of the C-terminal tail of the receptor may partly explain the 
absence of agonist-induced activity in the case of the A2AR-GL31. Klinger and 
colleagues showed that a truncated version of the A2AR (1-311) exhibited no 
constitutive activity at all in a cAMP assay compared with the wild-type (Klinger et 
al., 2002b). However, the A2AR-GL31 construct shows similar levels of constitutive 
activity in the cAMP assay compared with the wild-type (Lebon et al., 2011b) despite 
the truncation of the C-terminal tail (1-316). 
 Although, the GTPγS and the cAMP assays have the advantage of assessing 
the receptor in a mammalian system or in insect cells, they also have their limitations. 
For instance, the GTPγS assay requires the handling of radioactive material, which 
has inherent disadvantages including cost and safety considerations. The cAMP assay 
requires expression of the mutants in mammalian cells, which is labour intensive and 
expensive. Furthermore, mammalian expression systems are complex and expression 
levels are often difficult to control and vary according to the type of cell used 
(Atwood et al., 2011). In addition, recombinant host cells may express more than one 
G protein, which may affect the pharmacological profile of the receptor studied. 
Indeed, the receptor of interest might interact with more than one G protein, which 
could make the data more difficult to interpret. 
For these reasons a simple, inexpensive and high-throughput signalling assay 
is required in order to functionally characterize the thermostable A2AR mutants. The 
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aim of the research in this chapter was to explore the suitability of a yeast GPCR 
signalling system for assessment of the function of the thermostabilised mutants. 
 
The yeast functional assay used for this study utilizes a modified S. 
cerevisiae strain, MMY24 (Brown et al., 2003), which has been genetically 
engineered to allow functional characterization of heterologous GPCRs. In this strain, 
the gene encoding Ste2p, the only yeast GPCR capable of coupling to the yeast 
pheromone pathway in a haploid cell, was deleted and a chimeric Gα subunit was 
introduced in which the five C-terminal amino acids of the yeast Gα protein Gpa1p 
were replaced with the corresponding residues from mammalian Gαi3 (Brown et al., 
2003). Therefore, the GPCR is isolated from its native environment and can be 
studied in combination with a single G protein species in a completely defined 
system. Receptor activation induces a reporter gene (FUS1-HIS3) in which HIS3, 
encoding the biosynthetic enzyme imidazoleglycerol-phosphate dehydratase, is under 
control of the pheromone-responsive FUS1 promoter. Stimulation of the pathway by 
GPCR activation allows the yeast to grow in media lacking histidine. Hence, growth 
of the cells in the absence of histidine but the presence of receptor specific agonist 
provides a measure of receptor activation and signalling. Growth of the cells is 
measured by changes in the levels of fluorescein, the product of the reaction between 
Fluorescein-Di-β-D-glucopyranoside (FDGlu) and exoglucanase, an endogenous 
yeast enzyme secreted from dividing cells (Fig 2-2) (Dowell & Brown, 2009). The 
output can be manipulated easily to obtain the required sensitivity by varying 
components such as 3-Amino Triazole (3AT) that is used to regulate both the 
background and also the reporter capacity. Since 3AT is an inhibitor of 
imidazoleglycerol-phosphate dehydratase, an essential enzyme for the biosynthesis of 
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histidine, 3AT is able to reduce any histidine production due to endogenous activity 
of this enzyme. Therefore only cells expressing functional receptors are able to grow 
in a media lacking histidine.  
 
Figure 2-2 Yeast growth functional assay.  Activation of the receptor after binding of an agonist 
induces expression of the FUS1-HIS3 reporter gene through the yeast pheromone pathway. The 
product of the HIS3 gene triggers production of Histidine allowing the yeast to grow in media lacking 
Histidine. Dividing cells produce exoglucanase which reduces FDGlu to Fluorescein producing 
fluorescence. 
 
The results presented in this chapter demonstrate that the optimum 
conditions to assess the pharmacological profiles of the A2AR mutants are when the 
genes are chromosomally integrated using the p306GPD vector, with an incubation 
time of 23 hours and a concentration of 3AT of 5 mM. 
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2.2 Materials and Methods 
 
2.2.1 Materials 
 
StuI, BamHI and HindIII restriction enzymes were purchased from New 
England Biolabs (Ipswich, MA, USA). The T4 DNA ligase kit and the QuickChange 
Lightning Site-Directed Mutagenesis kit were obtained from Agilent technology 
(Wokingham, UK) while Fluorescein Di-β-D-Glucopyranoside was obtained from 
Invitrogen (Paisley, UK). The amino acids, as well as the Yeast Nitrogen Base 
(YNB), the adenosine deaminase and the 3AT were purchased from Sigma (Haverhill, 
UK). The glucose was obtained from Merck (Nottingham, UK) and the protease 
inhibitor tablets from Roche (Burgess Hill, UK). The Tris-HCl and the glycerol were 
purchased from AnalaR NORMAPUR. 
2.2.2 Construct generation  
 
Rant5, Rant21 and Rag23 A2AR mutants were obtained from GeneArt 
(Regensburg, Germany). All synthetic genes encoded the full-length A2AR gene, 
contained a FLAG tag at the N terminus and were codon optimized for S. cerevisiae. 
The genes were cloned into the pDDGFP S. cerevisiae expression plasmid (Newstead 
et al., 2007) by homologous recombination exactly as described by Drew and 
colleagues (Drew et al., 2008) using the primers detailed in table 2-1. This places the 
gene encoding the A2AR upstream of the gene coding for GFP-His8. The pDDGFP 
plasmids were then digested using BamHI and HindIII which excised the complete 
gene coding for the A2AR + GFP-His8 fusion proteins (Fig 2-3). These genes were 
then ligated into three different expression vectors, p306GPD, p426GPD and 
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p426GPD-L3, using T4 DNA ligase. p426GPD is an episomal vector with 2µ 
replication origin and has been fully described previously (Mumberg et al., 1995). 
p426GPD-L3 is similar to p426GPD but contains the α-factor signalling sequence 
and p306GPD is an integrating vector based on the pRS306 vector (Sikorski & Hieter, 
1989) with a modified promoter. The wild-type A2AR was generated from the Rant5 
synthetic gene by site-directed mutagenesis using the QuickChange Lightning Site-
Directed Mutagenesis kit and the primers detailed in Table 2.2. 
Table 2-1 Primers used to clone the A2AR mutant genes in the pDDGFP vector by homologous 
recombination. The primer contains a gene specific sequence and an overhang region used for the 
homologous recombination into 2 µ S. cerevisiae GFP-fusion vector. 
Primer Sequence 
A2A forward tcgacggattctagaactagtggatcccccatggattacaaggatgatgatgatgc 
A2A A316_reverse Aaattgaccttgaaaatataaattttccccggcctttgaatggttcttgttg 
 
Table 2-2 Mutagenic primers used to generate the intermediate mutant A2AR constructs. 
Primer Sequence (5' to 3') 
L54A_forward cgttgtttctttggctgctgctgatattgcggttggtgttttagc 
L54A_reverse gctaaaacaccaaccgcaatatcagcagcagccaaagaaacaacg 
A88T_forward cttgcttcgttttggttttgactcaatcttctatcttctcc 
A88T_reverse ggagaagatagaagattgagtcaaaaccaaaacgaagcaag 
A239V_forward ctaagtccttggctattatagttggtttgttcgctttgtgttg 
A239V_reverse caacacaaagcgaacaaaccaactataatagccaaggacttag 
 
2.2.3 Expression vector optimization 
 
In order to determine the best expression vector for the yeast functional 
assay, the Rag23, Rant5 and Rant21 mutants, containing the GFP-His8 tag, were 
cloned into the three different expression vectors: p426GPD, p426GPD-L3, 
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containing the α factor signalling sequence and p306GPD (Dowell & Brown, 2009). 
All three vectors contain the strong GPD constitutive promoter. While the p306GPD 
is an integrating vector, both p426GPD are episomal vectors.  
 
Figure 2-3 Schematic representation of the adenosine A2AR constructs used for the functional 
assay: The FLAG tag precedes the A2AR gene, which is then followed by a Tobacco etch virus (TEV) 
cleavage site present to remove the GFP and the 8 His TAG after purification. 
 
The three different A2AR vector constructs were transformed using the 
lithium-acetate procedure (Gietz and Schiestl, 2007) (see appendix 6.3). Prior to 
transformation, the p306GPD plasmids containing the genes of interest were digested 
for one hour at 37°C with StuI and subsequently chromosomally integrated at the 
ura3 locus in the MMY24 (MATa fus1::FUS1-HIS3 LEU2::FUS1-lacZ 
far1 sst2 ste2 gpa1::ADE2 his3 ura3 trp1 Gpa1p/Gai3) yeast strain (Dowell and 
Brown, 2009).  
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2.2.4 In-gel fluorescence 
 
The presence of the GFP tag was used to monitor the expression and quality 
of the protein produced. The -URA agar transformation plates were first screened 
after three days incubation at 30°C, using a mercury lamp coupled to a microscope to 
detect green colonies. Then for each mutant, three green colonies were inoculated in 
10 ml of –URA media (6.7g YNB, 2% D-glucose, 1.92g/L amino acid supplement 
(23.53 mg of L-arginine (HCl), 117.6 mg of L-aspartic acid, 117.6 mg of glutamic 
acid (monosodium), 35.29 mg of L-lysine, 23.53 mg of L-methionine, 58.82 mg of L-
phenylalanine, 441.2 mg of L-serine, 235.3 mg of L-threonine, 35.29 mg of L-
tyrosine and 176.5 mg of L-valine) supplemented with 2% glucose and histidine to a 
final concentration of 20 mg/L, in 50 ml aerated capped tubes. Cultures were 
incubated at 30°C overnight with shaking at 300 rpm. Cells were harvested by 
centrifugation at 4 000 g for 10 mins. The supernatants were removed and the cell 
pellets resuspended in 500 µl of ice cold Yeast Suspension Buffer (YSB) (50 mM 
Tris‐HCl (pH7.6), 5 mM EDTA, 10% glycerol, 1 complete protease inhibitor cocktail 
tablet (Roche) per 20ml buffer) and transferred into 1.5 ml Eppendorf tubes. 200 mls 
of acid washed glass beads were added and the tubes were shaken at a frequency of 
20 sec-1 for 10 mins, using a Tissue Lyser to break the cells. The tubes were then 
centrifuged at 2 000 g for 15 sec and the supernatants harvested in clean Eppendorf 
tubes and 500 µl of ice cold YSB added to the cell debris. The operation was 
repeated, the supernatants collected again and combined with the previous 
supernatants. The combined supernatants were then centrifuged at 13 000 g for 1 hr. 
The supernatants were removed and discarded and the membrane pellets resuspended 
in 100 µl of ice-cold YSB. A 10 µl aliquot of membrane suspension was mixed with 
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an equal volume of 2X Novex Tris-Gly SDS-PAGE sample buffer (Invitrogen) for 
each preparation and the proteins separated on a Novex 12% Tris-Gly gel 
(Invitrogen). The Benchmark Fluorescent protein markers (Invitrogen) were used as 
protein standards. The fluorescent protein bands were detected using a LAS‐1000-
3000 charged-coupled device (CCD) imaging system (Fujifilm) with an excitation 
wavelength of 460 nm. 
In-gel fluorescence analysis of Rant21 was performed in both the presence 
and absence of protease inhibitors (PI). One complete protease inhibitor cocktail 
tablet (Roche) was dissolved in 50 ml of YSB. Cell pellets were then resuspended 
either in YSB or in YSB+PI. 
2.2.5 Confocal microscopy 
 
For each mutant, the same three colonies used for the in-gel fluorescence 
were inoculated in 10 ml of -URA media supplemented with 2% glucose and histidine 
to a final concentration of 20 mg/L, in three different 50 ml aerated capped tubes. 
Cultures were incubated at 30°C overnight with shaking at 300 rpm. Cells were 
harvested by centrifugation at 4 000 g for 10 mins and the supernatant removed and 
discarded. A 6 µl of each cell pellet was mixed individually with 24 µl of PBS (137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and 100 µl of parafix. 
Each sample mixture was dispensed into individual well of a black 96 well plate 
(Costar). After 30 mins to allow cells to settle, the supernatants were carefully 
removed and 50 µl of PBS added to each well. Localization of the properly folded 
mutants containing the GFP tag was detected using a TCS SP5 II confocal microscope 
from Leica. 
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2.2.6 Yeast cell growth assay 
 
The mutants expressed in MMY24 were inoculated in –URA media 
supplemented with histidine to a final concentration of 20 mg/L, overnight at 30°C. 
The cultures obtained were diluted into –URA media supplemented with 26.1 mM 
Na2HPO4.7H2O, 21.1 mM NaH2PO4 pH 7.0 to an OD600 of 0.02. The assay mix was 
supplemented with 3-aminotriazole (3AT), to a range of final concentrations (see 
below for details). Fluorescein Di-β-D-Glucopyranoside (FDGlu) was also added to 
the media to a final concentration of 20 µM. 100 µl of this mix was dispensed across 
20 wells of a 96-well plate. 20 different concentrations of NECA, ranging from 0.20 
mM to 0.17 pM, were then dispensed across the 20 wells and the plate incubated at 
30°C. Yeast growth was assessed by fluorescence measurement using a micro-plate 
reader (TECAN Ultra Evolution) 23 hours or 44 hours following incubation at 30°C. 
Log10 [NECA] against fluorescence curves were plotted and fitted to non-linear 
regression, providing EC50 values. Data were analyzed using GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA, USA). 
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2.2.7 Optimisation of assay conditions 
 
Different aspects of the assay can be modified to optimize the signal window 
and to increase the signal to noise ratio. The first parameter examined was the 
incubation time at 30°C. The fluorescence readings were therefore performed after 23 
hours and after 44 hours, in order to monitor the importance of incubation time for the 
assay. While optimizing the incubation time, a concentration of 2 mM 3AT was used. 
As mentioned earlier, the 3AT plays a crucial role in knocking out the 
endogenous activity of the imidazoleglycerol-phosphate dehydratase. However, it is 
important to optimize the concentration of 3AT in the assay, to make sure that it does 
not interfere with the response triggered by the activation of the receptor and to get a 
good signal window which is defined as the ratio of maximum response : lower 
response being greater than two. Seven different concentrations were used to 
determine the most suitable one for this assay. Different volumes of a 1 M stock 
solution were added to the assay mixture to obtain the final following concentrations: 
0 mM, 0.5 mM, 1 mM, 2 mM, 5mM, 10 mM and 20 mM. 
Finally, the influence of endogenous adenosine on the assay results was 
investigated by addition of adenosine deaminase (ADA) to the assay mixture to a final 
concentration of 100 µM and results were compared with the assay run in the absence 
of adenosine deaminase both for Rag23 and the wild-type A2AR. For this analysis, 5 
mM of 3AT were used. 
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2.3 Results 
 
2.3.1 p306GPD vector is the most suitable vector for the 
yeast functional assay 
 
The three mutants, namely Rag23, Rant5 and Rant21, were expressed using 
three different expression vectors: p426GPD, p426GPD-L3 (containing a signalling 
sequence allowing proper trafficking of the receptor) and p306GPD. In each case 
protein expression is under control of the GPD constitutive promoter. p426GPD and 
p426GPD-L3 are episomal vectors while p306GPD vector is an integrating vector. 
 
Figure 2-4 SDS-PAGE In-gel fluorescence analysis of Rant5 and Rag23 cloned in p306GPD, 
p426GPD and p426GPD-L3.expressed in the MMY24 yeast strain 
 
The in-gel fluorescence shows a faint band of approximately 65 kDa for all the 
lanes. This band is commonly seen when running in-gel fluorescence on membranes 
obtained from S. cervisiae and corresponds to a nonspecific autofluorescent protein 
(Newstead et al., 2007). For Rag23 and Rant5 in p306GPD, three strong bands can be 
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seen on the gel, one of which corresponds to the A2AR fused to the GFP (Fig 2-4). 
The other two bands are likely to be degradation products. No other band than the 
faint band at 65 kDa is observed when the constructs are cloned in the p426GPD or 
the p426GPD-L3 vectors. Addition of protease inhibitors did not improve the profiles 
observed. This could mean that either the protease inhibitors used are not efficient 
against the proteases degrading the protein or that the degradation observed is not due 
to protease activity but might be due to modification of the plasmid. 
To further assess which one of the expression vectors was the most suitable for 
the assay, localization of the receptor fused to the GFP was monitored using confocal 
microscopy. Only the Rag23 and the Rant5 mutants were examined in this case. For 
Rag23, the images show a high number of cells expressing the receptor, with most of 
the cells showing green fluorescence and localization to the membrane when the 
mutant was cloned into the p306GPD vector (Fig 2-5A). However, when cloned into 
the p426GPD or into the p426GPD-L3 vectors, only a very small number of cells 
were green and the amount of receptor trafficking to the plasma membrane was much 
lower than observed for the p306 vector  (Fig 2-5B and C). 
 
Figure 2-5 Confocal imaging for Rag23 cloned into the p306GPD vector (picture showing only 
fluorescent cells obtained with the x63 lens) (A), the p426GPD vector (picture showing both 
fluorescent and non fluorescent cells obtained with x40 lens) (B) and the p426GPD-L3 vector (picture 
showing both fluorescent and non fluorescent cells, obtained with the x25 lens) (C). 
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Similarly, the expression of the Rant5 in p306GPD is high, as shown by the 
number of green cells (Fig 2-6A). Based on GFP fluorescence, the mutant seems to be 
trafficked properly into the cellular membrane. However, when cloned into the 
p426GPD or the p426GPD-L3, the number of cells expressing the receptor is low (Fig 
2-6B and C) and only receptor produced by the p426GPD-L3 construct is correctly 
trafficked to the membrane. 
 
Figure 2-6 Confocal imaging for Rant5 cloned into the p306GPD vector (picture showing only 
fluorescent cells obtained with the x63 lens) (A), the p426GPD vector (picture showing both 
fluorescent and non fluorescent cells obtained with x40 lens) (B) and the p426GPD-L3 vector (picture 
showing both fluorescent and non-fluorescent cells, obtained with the x63 lens) (C). 
 
2.3.2 Incubation time and 3AT concentration are critical 
 
As the read out of this assay is a measure of the growth of the yeast, the 
incubation time before taking the readings is a crucial parameter of this assay. Two 
different incubation times were investigated using the Rag23 mutant: 23 hours and 44 
hours. In both cases the three previously used expression vectors were investigated. 
The Rag23 mutant, cloned into the p306GPD expression vector yielded a dose-
response curve with a positive signal window after 23 hours of induction at 30°C (Fig 
2-8A), as demonstrated by the difference between the maximum and the minimum 
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responses. After 44 hours, although there was still a dose-response curve, the noise 
has increased significantly compared to the 23 hours incubation time (Fig 2-7B).  
 
Figure 2-7 Incubation time optimization using the Rag23 mutant cloned into the p306GPD, p426GPD 
and the p426GPD-L3 expression vectors. Cells were incubated for 23 hours (A) and 44 hours (B) prior 
to readings being taken. Data points are the average of one experiment performed in triplicate. 
 
When cloned into the p426GPD expression vector, the Rag23 gave a dose-
response curve with a very small signal window after 23 hours (Fig 2-7A). After 44 
hours cells expressing this construct showed very high levels of growth regardless of 
the concentration of agonist applied (Fig 2-7B).  
After 23 hours, the Rag23 mutant cloned in p426GPD-L3 displayed no growth 
at all regardless of the concentration of agonist used (Fig 2-8A). However, after 44 
hours of incubation, a dose-response curve can be observed (Fig 2-7B). All further 
work was carried out using the p306GPD vector with a 23 hours incubation time. 
As mentioned earlier, another critical parameter of this yeast growth assay is the 
concentration of 3AT, an inhibitor of the imidazoleglycerol-phosphate dehydratase. 
Seven different concentrations of 3AT were investigated using the wild-type A2AR 
cloned into the p306GPD expression vector. Readings were taken following 23 hours 
incubation at 30°C. When 0 mM, 0.5 mM and 1 mM final concentration of 3AT were 
used there is no dose-response curve observed, due to very high background (Fig 2-8). 
When the 3AT concentration was increased to 2 mM, a dose-response curve can be 
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seen but the signal window is very small due to a very high background. When 5 mM, 
10 mM and 20 mM of 3AT were used, dose-response curves were obtained with good 
signal windows. However, only at 5 mM 3AT was the maximum response not 
affected, thus this concentration was used for further experiments. 
 
Figure 2-8 3AT concentration optimization: 7 different concentrations of 3AT were investigated using 
the wild-type A2AR cloned in the p306GPD vector. Data points are the average of one experiment 
performed in triplicate. 
 
The effect of any potential endogenous adenosine on the output of the assay was 
investigated by the addition of Adenosine deaminase. Fig 2-9 clearly shows that the 
addition of ADA did not affect the data meaning that endogenous adenosine is not 
interfering with the assay also demonstrating that it was not necessary to add ADA to 
further assays. 
 89 
 
Figure 2-9 Effect of ADA on the activity profiles of the wild-type A2AR and the Rag23 with 5 mM of 
3AT. Data points are the average of one experiment performed in triplicate. 
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2.4 Discussion 
 
The yeast functional assay required optimization in order to be utilized for 
the studies of the WT and mutant A2ARs. The first step of assay optimization involved 
assessment of which expression vector resulted in adequate expression levels and 
correct localization of the receptors within the cells. The constructs containing the 
GFP were cloned in three different expression vectors. The quality of the protein 
expressed was monitored by in-gel fluorescence while localization was monitored by 
confocal microscopy. Incubation time with agonists, concentration of 3AT and role of 
endogenous adenosine were also investigated.  
The p306GPD integrating vector gave the best expression levels and 
membrane localization. It is unclear why the integrating vector gave better results 
than the episomal vectors. 
Investigation of the optimal incubation time with agonist was also assessed 
using the functional assay. The results confirmed the earlier finding indicating that 
using the p306GPD vector resulted in higher receptor expression. As shown in Figure 
2-7, after 23 hours a dose-response curve is observed when the mutant was cloned 
into the p306GPD vector. When expressed using the p426GPD vector, although a 
dose-response curve is observed after 23 hours, the signal window is greatly reduced. 
This is mainly due to a very low efficacy achieved at saturating concentrations of 
agonist, consistent with low expression levels. When cloned into the p426GPD-L3 
vector, the Rag23 shows no dose-response curve at all after 23 hours. 
However, after 44 hours incubation time, the profiles observed are quite 
different. Indeed, the Rag23 cloned into the p306GPD vector still exhibits a dose-
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response curve but with an increase noise signal. The Rag23 cloned into the 
p426GPD shows very high level of growth regardless of the concentration of agonist 
used.  
In contrast, the Rag23 cloned into the p426GPD-L3 vector now shows a 
dose-response curve. This data indicate that when using the p426GPD-L3 expression 
vector, there is a delay in expression and trafficking of the receptor. Indeed, the in-gel 
fluorescence and confocal data were obtained after overnight cultures and showed no 
detectable expression of the protein. This was confirmed by the lack of signal in the 
functional assay. However, after 44 hours, the yeast seems to be expressing some 
functional protein as demonstrated by the dose-response curve obtained in the yeast 
growth assay. 
Obtaining a clear signal window is important in order to achieve high assay 
sensitivity. Especially since it is expected that a range of different functional profiles 
will be observed. The 5 mM 3AT concentration was chosen for future assays for two 
reasons. Firstly, when using 5 mM of 3AT, the maximum response obtained at 
saturating concentrations of agonist is the same as obtained when using no 3AT. In 
contrast, both 10 and 20 mM 3AT reduced the maximum response. This means that 
the 3AT is not limiting the maximum response when using 5 mM. Secondly, when 
using 5 mM of 3AT, the signal window obtained was around two. 
Finally, the addition of adenosine deaminase has no effect on the functional 
profiles of the wild-type and Rag23 receptor constructs in the yeast growth assay. 
This indicates that there is no interference from endogenous adenosine in this assay. 
Indeed, if adenosine had any effect at all, this should be reduced by the addition of 
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ADA, which metabolizes any adenosine present. Therefore ADA was not added when 
further assays were performed.  
In summary, a yeast cell-based receptor-signalling assay was optimized to 
allow assessment of the functional profiles of the wild-type and thermostabilised 
mutant A2AR constructs. The p306GPD vector was chosen for expression since it 
gave the best results in terms of functional expression and localization of the 
receptors. In addition, the optimal incubation time used following this study was 23 
hours in the presence of 5 mM of 3AT and no ADA. Using this set of conditions, this 
assay was optimized to provide a robust, high throughput and inexpensive tool to 
functionally characterize a set of thermostable A2AR mutants. 
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3 Functional characterizations of the 
Rag23, Rant5, Rant21 and some 
intermediate mutants 
 
 
 
 
 
 
 
Part of the work presented here has been published in: 
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Loss of constitutive activity is correlated with increased 
thermostability of the human adenosine A2AR 
 
Nicolas Bertheleme, Shweta Singh, Julia Hubbard, Simon Dowell, Bernadette Byrne 
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3.1  Introduction 
 
Three of the most thermostable A2AR mutants generate by alanine-scanning 
mutagenesis (Magnani et al., 2008) were investigated using both the yeast assay and a 
radioligand binding assay. One of these mutants is in a preferentially agonist-binding 
conformation (Rag23) and contains the following five mutations: F79A, A184L, 
R199A, L208A and L272A. The other two are preferentially in an antagonist-binding 
conformation (Rant5 and Rant21) and contain respectively the following three and 
four mutations: A54L, T88A and V239A; A54L, T88A, K122A and V239A.  
Here the effects of these mutants on A2AR function are explored using the 
yeast cell growth assay described in the previous chapter. To further investigate the 
effect of individual mutations on the pharmacological profile of the receptor, 
intermediate mutants, between Rant5 and WT containing one or two mutations were 
generated and also characterized in the yeast cell growth assay.  
In addition, Rag 23.1, an intermediate mutant between Rag 23 and WT in 
which the L208A was mutated back to the original leucine was characterised. The 
Rag 23.1 mutant was investigated because of the crucial localisation of L208 in ICL3. 
Using the previously optimized yeast growth assay, three pharmacological 
parameters of the receptor constructs were examined. Firstly, the efficacy is a 
measure of the maximum response obtained when saturating concentrations of agonist 
are used (Fig 3-2). It represents how efficiently the receptor is able to activate its 
cognate G protein when fully activated by an agonist. Secondly, the constitutive 
activity is a measure of the activity of the receptor in the absence of agonist (Fig 3-2). 
It can be graphically illustrated as shown in figure 3-2 by the receptor activity at very 
 95 
low concentrations of agonist. Finally, the potency is defined as the concentration of 
agonist necessary to obtain fifty percent of the maximum agonist-induced response 
(Fig 3-1). The potency is represented either by the EC50 or the pEC50. Therefore, this 
assay allows us to make the distinction between agonist-induced activity and 
constitutive activity. 
 
Figure 3-1 Dose-response curve illustrating the concepts of efficacy, potency and constitutive activity. 
The efficacy is graphically illustrated by the plateau reached at saturating concentrations of agonist. 
The constitutive activity is graphically illustrated by the plateau reached at very low concentrations of 
agonist. The potency is illustrated by the red lines. 
 
The data presented in this chapter indicate that there is a correlation between 
loss of constitutive activity and thermostability. Furthermore, the data suggest that the 
agonist-induced and constitutively active conformations are distinct. 
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3.2 Material and Methods 
 
3.2.1 Material 
 
Yeast nitrogen base and yeast extract were purchased from Difco. Peptone, 
L-histidine, EDTA, EGTA, bovine serum albumin, Folin-Ciocalteau reagent, amino 
acids, 3AT, trichloro acetic acid, adenosine and theophylline were obtained from 
Sigma-Aldrich and dimethyl sulfoxide (DMSO) was purchased from Acros Organics 
(Geel, Belgium). Scintillation cocktail (Ultima Gold MV) and [3H]NECA were 
obtained from PerkinElmer (Cambridge, UK). [3H]ZM241385 was obtained from 
American Radiolabelled Chemicals Inc. (Royston, UK), while ZM241385 and NECA 
were obtained from Tocris (Abingdon, UK). GF/B filters were from Whatman (Little 
Chalfont, UK). The Lightning Quikchange site directed mutagenesis kit was obtained 
from Agilent technology (Wokingham, UK). Fluorescein Di-β-D-Glucopyranoside 
was purchased from Invitrogen (Paisley, UK). 
3.2.2 Site-directed mutagenesis 
 
The wild-type A2AR and most of the intermediate mutants were generated 
from the Rant5 synthetic gene by site-directed mutagenesis using the QuickChange 
Lightning Site-Directed Mutagenesis kit and the primers detailed in Table 3-1. 
The Rag23.1 intermediate mutant (F79A, A184L, R199A, L272A), was 
obtained from the Rag23 synthetic gene by site-directed mutagenesis using the 
QuickChange Lightning Site-Directed mutagenesis kit and the primers detailed in 
Table 3-1. 
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Table 3-1 Mutagenic primers used to generate the intermediate mutant and wild-type A2AR constructs. 
Primer Sequence (5' to 3') 
L54A_forward cgttgtttctttggctgctgctgatattgcggttggtgttttagc 
L54A_reverse gctaaaacaccaaccgcaatatcagcagcagccaaagaaacaacg 
A88T_forward cttgcttcgttttggttttgactcaatcttctatcttctcc 
A88T_reverse ggagaagatagaagattgagtcaaaaccaaaacgaagcaag 
A239V_forward ctaagtccttggctattatagttggtttgttcgctttgtgttg 
A239V_reverse caacacaaagcgaacaaaccaactataatagccaaggacttag 
A208L_forward ctattttcttggctgccagaagacaactaaagcaaatggaatctcaacc 
A208L_reverse ggttgagattccatttgctttagttgtcttctggcagccaagaaaatag 
V239I_forward ctgccaagtcactggccatcattatagggctctttgcc 
V239I_reverse ggcaaagagccctataatgatggccagtgacttggcag 
 
3.2.3 Expression  
 
Since the level of constitutive activity as well as the efficacy of the different 
constructs will be compared, it is essential to estimate the expression levels of each 
mutant produced in the yeast system. Indeed, the levels of constitutive activity and 
efficacy are dependant on the number of functional receptors per cell. In contrast, the 
potency is not affected by expression levels. As described in chapter 2, all the A2AR 
constructs were fusions with a C-terminal GFP-8His tag in the p306GPD vector, 
transformed using the lithium-acetate procedure (Gietz & Schiestl, 2007) and 
chromosomally integrated at the ura3 locus in the MMY24 (MATa fus1::FUS1-HIS3 
LEU2::FUS1-lacZ far1 sst2 ste2 gpa1::ADE2 his3 ura3 TRP1::GPA1-Gai3) yeast 
strain (Dowell & Brown, 2009). The wild-type and Rag23.1 constructs were also 
transformed into the MMY11 (MATa fus1::FUS1-HIS3 LEU2::FUS1-lacZ far1 sst2 
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ste2 gpa1::ADE2 his3 ura3 TRP1) yeast strain which has the same genotype as 
MMY24 but lacks the Gα protein. Estimation of the expression levels for all the 
constructs was obtained from the Bmax values obtained from the saturation binding 
assays. In addition, the fluorescence of the GFP was also used as previously described 
(Drew et al., 2008). Briefly, 10 ml of yeast culture expressing the desired protein 
were centrifuged at 4000 g for 10 minutes and resuspended in 200 µl of PBS. 200 µl 
were transferred into a black 96-well plate and the relative fluorescence units (RFU) 
were measured using a SpectraMax M2e from Molecular Devices. The process was 
also performed with 10 ml of yeast culture not expressing the protein. The GFP 
concentration was obtained using the RFU of a known concentration of GFP in a final 
volume of 200 µl with the following formula: 
 
Conc GFP = (RFUprotein – RFUno protein) x (known Conc of GFP) / RFUGFP 
 
This concentration was then divided by 40 and multiplied by 0.6 to 
determine the concentration in the 200 µl of buffer and to account for the recovery, 
which is typically 60%. This was then multiplied by the mass of the desired protein 
and divided by the mass of GFP to obtain the membrane protein overexpression in 
mg/L of culture. 
 
 
 
 
 
 
 99 
3.2.4 Membrane preparation 
 
Cells were resuspended in cold breaking buffer (50 mM Tris.HCl (pH7.6), 1 
mM EDTA, 0.6 M sorbitol, 1 tablet of protease inhibitor for 100 ml). Glass beads 
were added to the suspension and cells were broken using a tissue lyser (Qiagen) set 
to 20 Mhz for 10 min. The suspension was then centrifuged at 4000 g for 1 min and 
the supernatant transferred to a new eppendorf tube. Cell debris and glass beads were 
resuspended and the same operation was repeated. Combined supernatants were then 
centrifuged at 13 000 g for 1 hour to collect the membranes. The supernatant was 
discarded and the membrane pellets resuspended in membrane buffer (20 mM 
Tris.HCl (pH7.5), 150 mM NaCl, 20% glycerol, 1 tablet of protease inhibitor for 100 
ml), flash frozen in liquid nitrogen and stored at -80°C. 
 
3.2.5 Protein concentration 
 
All protein concentrations were determined as previously described (Lowry 
et al., 1951; Singh et al., 2010). A stock solution of BSA at 1 mg/ml was used to 
generate a standard curve. 0, 5 10, 20, 40, 60, 80, 100 µL of the stock solution were 
dispensed in eppendorfs in triplicate in addition to 5 and 10 µL of the test protein. 1 
ml of 10% trichloro acetic acid (TCA) was added to all tubes, which were vortexed 
immediately. The tubes were centrifuged at 4000 g for 15 min. The supernatant was 
discarded and the precipitate dried for 10 min. 650 µl of a solution containing Lowry 
solution A (2% anhydrous Na2CO3, 0.1 M NaOH), Lowry solution B (4% 
CuSO4.5H20) and Lowry solution C (2% NAK tartrate) at a 100/1/1 ratio were added. 
The tubes were vortexed immediately and incubated at room temperature for 10 min. 
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The Folin-Ciocalteau reagent was diluted with an equal volume of water and 100 µl 
of this solution was added to each tube. The tubes were vortexed immediately and 
incubated at room temperature for 10 min. 650 µL of ddH20 was added to each 
condition and the tubes were vortexed immediately. The OD760 absorbance values 
were plotted versus the BSA concentration. The amount of protein in the test sample 
was calculated from the standard curve using GraphPad Prism 5.0 (GraphPad 
Software, San Diego, CA, USA). 
3.2.6 Saturation binding assay 
 
For saturation assays membranes expressing the WT or mutant A2AR forms 
were incubated with [3H]ZM241385 (0.036 – 20 nM) in binding buffer (20 mM 
HEPES pH 7.4, 1 mM EDTA,1 mM EGTA, 0.1% BSA). Non-specific binding was 
defined in the presence of 10 mM theophylline at each concentration. The WT and 
Rag23.1 membranes, prepared in the absence of NaCl, were also incubated with 
[3H]NECA (0.3-300 nM) in an alternative binding buffer (20 mM HEPES pH 7.4, 1 
mM EDTA, 1 mM EGTA, 0.1% BSA, 10 mM MgCl2). Non-specific binding was 
defined in the presence of 10 mM theophylline at each concentration. Assays were 
performed at least in duplicate in a final volume of 1 ml containing 20 µg of 
membrane protein in each tube. The reactions were incubated for 3 h at room 
temperature. Following incubation, receptor bound radioligand was collected by 
filtration through Whatman glass micro-fibre GF/C filters which were then placed in 
individual scintillation vials containing 2 ml of Ultima GoldTM XR scintillation fluid. 
The filters were allowed to soak for at least six hours before the radioactivity was 
determined using an LS 6500 Beckman Coulter scintillation counter. 
 101 
The data were obtained as Disintegration Per Minute (DPM), which were 
then converted in radioligand concentrations (pmol) using the specific activity of the 
ligand. Finally, the data were plotted as pmol of radioligand bound by mg of protein 
against the free concentration of radioligand added. The curves were fitted to a non-
linear regression using a one-site binding model. This provided two parameters: the 
dissociation constant Kd and the Bmax. The Kd is defined as the concentration of ligand 
needed to occupy half of the receptor binding sites and therefore is a measure of the 
affinity of the ligand for the protein. The Bmax represents the maximum number of 
receptor binding sites occupied at saturating concentrations of ligand. Therefore, it is 
a measure of the number of functional binding sites. 
 
3.2.7 Competition binding assay 
 
Agonist competition binding profiles for the WT and mutant receptor forms 
were determined by competition binding assays. 20 µg of membrane protein 
containing WT and mutant A2AR were incubated with a fixed concentration of  
[3H]ZM241385 (2 nM for Rant5, Rant21 and T88A and 9 nM for Rag23) and varying 
concentrations of competing NECA (100 µM to 1 nM for WT and Rag23 and 10 mM 
to 10 nM for Rant5, Rant21 and T88A) or Adenosine, in a final volume of 1 ml 
binding buffer. Non-specific binding was defined in the presence of 10 mM 
theophylline. Initiation, incubation and termination procedures were as described for 
the saturation binding assay. 
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3.2.8 Yeast cell growth assay 
 
The yeast cell growth assay was performed as described in Chapter 2; 
Section 6. The RFU measured were normalised to the WT in each experiment. 100% 
represents the maximum response of the WT and 0% represents the response obtained 
in the absence of receptor. 
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3.3 Results 
 
3.3.1 Expression levels 
 
As mentioned previously, monitoring expression levels of each mutant form 
of the receptor is important in order to be able to accurately compare the constitutive 
activities and efficacies of the different constructs. This was done by measuring the 
fluorescence of GFP. The Bmax values obtained from the saturation binding assays are 
also a measure of the expression levels. However, in the case of the Bmax, the values 
are generated after membrane preparation. During this process, some of the protein 
may be degraded and the amount that is lost is likely to be construct-dependent. This 
may explain the discrepancies seen in the expression levels assessed by eGFP 
measurement and radioligand binding analysis. Results are summarized in table 3-2. 
 
Table 3-2 Expression levels of the different A2AR + eGFP constructs in the MMY24 strain.  
Constructs Expression (mg/ml) Bmax±SEM (pmol/mg) 
WT 0.8 1.1±0.2 
Rag23 1.0 5.1±0.4 
Rag23.1 1.1 1.8±0.7 
Rant5 1.2 6.5±0.5 
Rant21 1.6 5.8±0.7 
A54L 1.1 ND 
T88A 1.1 2.5±0.1 
V239A 1.0 ND 
A54L+T88A 0.7 ND 
A54L+V239A 0.9 ND 
T88A+V239A 1.2 ND 
The expression levels of all constructs were calculated from the relative fluorescence units as described 
in Drew et al. (2008). The Bmax values of the WT, Rant and Rag constructs were assessed by 
radioligand binding analysis of membrane bound receptor. ND: not determined. 
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In general, the expression levels expressed as mg/ml are similar for the 
different constructs. The major discrepancy concerns the wild-type and the Rant21. 
However, this does not influence our conclusions since the wild-type exhibits higher 
constitutive activity and efficacy than the Rant21 despite a lower expression level (see 
Fig 3-2). 
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3.3.2 Pharmacological profiles of the WT and mutants A2AR 
 
3.3.2.1 Wild-type, Rag23, Rant5 and Rant21 
 
3.3.2.1.1 The Yeast cell growth assay 
 
A summary of the pharmacological data for the constructs is given in Table 
3-3. In the yeast cell assay, increases in fluorescence due to the production of 
fluorescein, report increases in cell growth driven by receptor activation. The wild-
type receptor exhibits high levels of constitutive activity, observed as cell growth in 
the absence of any receptor agonist (Fig 3-2A, Table 3-3). The constitutive activity 
represents more than 50% of the total activity of the wild-type receptor. This is 
consistent with the high level of A2AR constitutive activity observed in a mammalian 
cell system as assessed by cAMP accumulation (Klinger et al., 2002a). Addition of 
the A2AR agonist, NECA, further activates the receptor in a concentration dependent 
manner (pEC50 = 7.5 ± 0.1; Fig 3-2A; Table 3-3). The constitutive activity of the 
wild-type was partially inhibited by inverse agonists (Fig 3-3). 
 
Figure 3-2 Functional data for the thermostabilised A2A mutants Rag23, Rant5 and Rant21 compared 
to WT expressed in the MMY24 S. cerevisae strain as constructs in the p306GPD vector. Data points 
are the average of three different experiments performed in triplicate. (A) WT, Rag23, Rag23.1 (B) 
WT, Rant5, Rant21.  
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Table 3-3 Pharmacological characteristics of the wild-type and mutants A2A forms.  
Receptor 
form 
NECA 
pEC50 ± SEM 
Constitutive activity ± SEM (% 
of max activity of WT) 
WT (n=3) 7.5 ± 0.1 54.8 ± 1.5 
Rag23 (n=3) 7.9* 6.1 ± 0.9 
Rant5 (n=3) ND 5.3 ± 0.4 
Rant21 (n=3) ND 3.5 ± 0.2 
Rag23.1 (n=2) 7.5* 3.6 ± 0.2 
*SEM=0 
Data are presented as mean ± standard error means of at least two independent experiments performed 
in triplicate. 
 
 
Figure 3-3 Pharmacological profiles of four different ligands using wild-type A2AR. The agonist 
NECA activates the receptor in a dose-dependent manner. The inverse agonists GW866133X and 
GSK124631A partially inhibit the constitutive activity. HU210, a selective CB2 agonist, was used as a 
negative control and displays no effect on the receptor. 
 
The Rag23, which is in a preferentially agonist-conformation exhibits a 
slight increase in potency compared with the wild-type and a decreased maximum 
efficacy (pEC50 = 7.9; Fig 3-2A; Table 3-3). The Rag23.1 intermediate mutant 
exhibits no constitutive activity and shows a similar potency to Rag23 with an 
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increased efficacy. Indeed, the efficacy of the Rag23.1 is similar to that of the wild-
type (Fig 3-2A). The Rant5 and Rant21 mutants, which are in a preferentially 
antagonist-conformation show no agonist-induced receptor activity (Fig 3-2B). 
Interestingly, in contrast to the wild-type, the thermostabilised mutants also show no 
constitutive activity (Fig 3-2, Table 3-3).  
3.3.2.1.2 Saturation and competition binding analysis in the MMY24 yeast strain 
 
Saturation binding analysis of the wild-type, Rag23, Rant5 and Rant21 
mutants reveals that all the receptor forms exhibit high affinity binding for the 
antagonist ZM241385 although the affinity of the Rag23, the thermostabilised agonist 
binding form is reduced by an order of magnitude compared to the other three 
receptor forms (Fig 3-4, Table 3-4). This is in agreement with the results reported for 
the expression of these receptor forms in E. coli (Magnani et al., 2008).  
 
Figure 3-4 Saturation binding of [3H]ZM241385 to S. cerevisae MMY24 membranes expressing the 
wild-type (A), Rag23 (B), Rant5 (C) and Rant21 (D) A2AR constructs. Data are representative of two 
independent experiments performed in triplicate. Bmax and Kd values were derived by non-linear 
regression analysis. Mean data ± SEM are presented in Table 3-4. 
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However the precise Kd values obtained in the yeast expression described 
here are significantly lower than those reported for the same constructs expressed in 
E. coli. For example a Kd of 0.85 nM was obtained here (Fig 3-4A, Table 3-4) for the 
wild-type receptor compared to 12 nM for the receptor in E. coli. The value reported 
here is consistent with the A2AR heterologously expressed in Pichia pastoris (Fraser, 
2006; Singh et al., 2010), S. cerevisiae (O'Malley et al., 2007) CHO cells (Dionisotti 
et al., 1997; Klotz et al., 1998) and A2AR present in rat brain tissue (Alexander & 
Millns, 2001). Competition binding analysis, using NECA as an agonist, reveals that 
while Rag23 binds the agonist NECA with reduced Ki compared to the wild-type (Fig 
3-5A and B, Table 3-4), the Rant5, Rant21 and T88A have dramatically increased Ki 
values (Fig 3-5C and D, Table 3-4). These results are consistent overall with those 
obtained for the same receptor constructs expressed in E. coli (Magnani et al., 2008). 
 
Figure 3-5 Binding of the low affinity agonist NECA to S. cerevisae MMY24 membranes expressing 
the wild-type (A), Rag23 (B), Rant5 (C) and Rant21 (D) A2AR constructs was assessed in competition 
with [3H]ZM241385. Data were fitted best to a one binding site model and are representative of two 
independent experiments performed in triplicates. Ki values were derived from experimentally 
determined IC50 values. Mean data ± SEM are presented in Table 3-4. 
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3.3.2.1.3 Saturation binding assay of the wild-type and Rag23.1 A2AR in 
MMY11 and MMY24 yeast strain using [3H]NECA 
 
It is possible that the lack of constitutive activity of the Rag23 and Rag23.1 
is the result of altered G-protein coupling for these mutants. The high efficacy of the 
Rag23.1 mutant following stimulation with ligand is strongly suggestive that the lack 
of constitutive activity seen in this mutant is not the result of reduced G-protein 
coupling. However, in order to investigate this further, binding of wild-type and 
Rag23.1 to [3H]NECA in the presence and absence of G-protein was determined. This 
was achieved by also expressing the receptor variants in an alternative yeast strain, 
MMY11 (Olesnicky et al., 1999), genetically identical to MMY24 but lacking the G 
protein alpha subunit. It is known that absence of G-protein reduces the affinity of a 
receptor for agonist (Ross et al., 1977; Yao et al., 2009). Thus if G-protein coupling 
has not been altered in the Rag23.1 mutant, the same level of reduction in affinity for 
[3H]NECA in the absence of G-protein for both the mutant and wild-type receptor 
forms should be seen. Saturation binding assay using [3H]NECA revealed that the 
binding affinity for the agonist of both the wild-type and Rag23.1 in the absence of G-
protein was reduced by an order of magnitude compared with the binding affinities in 
the presence of G-protein (Fig 3-6, Table 3-4), demonstrating that the mutant does not 
have altered G-protein coupling. 
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Figure 3-6 Saturation binding of [3H]NECA to S. cerevisae membranes expressing the wild-type in 
MMY24 (A), wild-type in MMY11 (B), Rag23.1 in MMY24 (C) and Rag23.1 in MMY11 (D) A2AR 
constructs. Data are representative of two independent experiments performed in duplicate. Kd values 
were derived by non-linear regression analysis. Mean data ± SEM are presented in Table 3-3. 
 
Table 3-4 Kd and Ki values for the different A2AR forms obtained from saturation and competition 
binding assay using [3H] ZM235481 and [3H]NECA as hot ligand and NECA and Adenosine as cold 
ligand. 
[3H]NECA Kd ± SEM 
(nM)‡ 
Receptor 
form 
[3H] 
ZM241385 
Kd ± SEM 
(nM) 
+ G-
protein 
- G-
protein 
NECA 
Ki ± SEM 
(µM) 
Adenosine 
Ki ± SEM 
(µM) 
WT 0.85 ± 0.08 8.6 ± 3.7 123.9±7.1 1.01 ± 0.23 0.36 ± 0.01 
Rag23 6.32 ± 0.34 - - 0.18 ± 0.02 - 
Rag23.1 - 1.6 ± 0.2 14.4 ± 1.3 - - 
Rant5 0.74 ± 0.05 - - 531 ± 300 - 
Rant21 0.63 ± 0.09 - - 247 ± 18 - 
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3.3.2.2 Intermediate mutants 
 
The functional profiles of the mutants intermediate between Rant5 and wild-
type show that the A54L mutant has reduced constitutive activity compared to wild-
type (Table 3-4). In addition while this mutant exhibits agonist-dependent receptor 
activity, its potency is greatly reduced compared with the wild-type receptor or Rag23 
(pEC50 = 7.0; Figure 3-7A; Table 3-5). 
 
Figure 3-7 Functional data for the thermostabilised A2A intermediate mutants expressed in the MMY24 
S. cerevisae strain as constructs in the p306GPD vector. Data points are the average of three different 
experiments performed in triplicate. (A) Single mutants; (B) Double mutants.  
 
 In contrast, the T88A mutant displays high levels of constitutive activity but 
has no detectable agonist-induced activity, whereas the V239A mutant has no 
detectable constitutive activity and shows lower sensitivity to NECA than A54L 
(pEC50 = 5.5 ± 0.1; Figure 3-7A; Table 3-5).  
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Table 3-5 Pharmacological characteristics of the intermediate mutants. Data are presented as mean ± 
standard error means of at least two independent experiments performed in triplicate. 
Receptor 
form 
NECA 
pEC50 ± SEM  
Constitutive activity ± SEM (% 
of max activity of WT) 
A54L 7.0* 25.0 ± 1.1 
T88A ND 39.8 ± 2.3 
V239 5.5 ± 0.1 2.5 ± 0.1 
A54L+T88A ND 46.4 ± 4.5 
A54L+V239 5.3 ± 0.1 2.6 ± 0.1 
T88A+V239 ND 3.4 ± 0.3 
*SEM=0. ND: not determined. 
The A54L + T88A and A54L + V239A mutants show almost identical 
activity profiles to that of the single T88A and V239A mutants respectively, while the 
T88A + V239A mutant shows a complete loss of both constitutive and agonist-
dependent activity (Figure 3-7B; Table 3-5).  
3.3.2.2.1 The effect of the T88A mutation 
 
In order to further explore the complete lack of agonist-induced activity 
observed for the T88A mutant, the functional profile of that mutant was investigated 
using a different agonist, adenosine. While NECA is no longer able to activate the 
T88A mutant, adenosine is still able to stimulate the mutant but with reduced potency 
compared to the wild-type receptor. Furthermore, the efficacy of adenosine is 
maintained in the T88A mutant (Fig 3-8, Table 3-6). Competition binding analysis, 
using adenosine as an agonist, reveals that the T88A has increased Ki compared to the 
wild-type (~6 fold increase), consistent with the decrease in pEC50 observed in the 
yeast growth assay (Table 3-6). 
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Figure 3-8 Activity of the T88A mutant compared to wild-type A2AR. The different receptor forms 
were expressed in the MMY24 S. cerevisae strain as constructs in the p306GPD vector. The cells were 
treated with increasing concentrations of either NECA (A) or adenosine (B). Data points are the 
average of three different experiments performed in triplicate. 
 
Table 3-6 Comparison of the NECA and adenosine binding and activation profile of T88A 
Receptor 
form 
NECA 
pEC50 ± SEM  
Adenosine 
pEC50 ± SEM 
NECA 
Ki ± SEM 
(µM) 
Adenosine 
Ki ± SEM 
(µM) 
WT 7.5 ± 0.1 6.4* 1.01 ± 0.23 0.36 ± 0.01 
T88A ND 4.5* 187 ± 54 2.75 ± 0.05 
ND: no detectable activity, *SEM=0 
 
As shown in Fig 3-8, the dose-response curve obtained for the T88A with 
adenosine as an agonist exhibits a biphasic nature. A possible explanation for this 
biphasic nature could be toxicity of the ligand at high concentrations. This was 
investigated by performing the assay with cells not expressing the receptor of interest 
but still containing the expression vector. Histidine was added to the assay media to a 
final concentration of 6 µg/ml in order to observe cell growth and potentially cell 
death at high concentration of adenosine. The results of this experiment showed no 
toxic effect on cell growth (Fig 3-9). The shape of the curve is therefore likely due to 
other pharmacological effects such as dimerisation of the receptor or allosteric 
binding of the adenosine. Further investigation would be needed to fully understand 
this phenomenon. 
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Figure 3-9 Effect of high concentrations of adenosine on cells not expressing the gene of interest but in 
the presence of histidine to observe a potential toxic effect of the ligand. Data points are the average of 
one experiment performed in triplicate. 
 
3.3.2.2.2 The effect of the V239A mutation 
 
Another interesting effect is the strong influence that the V239A mutation 
has on constitutive activity. Indeed, every mutant containing this particular 
substitution exhibits a complete loss of constitutive activity. Since the mutation 
involves changing one uncharged residues for another, it is likely that the effect 
observed is due to the reduction in size of the side chain. To further investigate the 
effect of the size of this residue, another mutant substituting V239 for a larger Ile 
residue (A54L+V239I) was generated and characterized (Fig 3-10).  
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Figure 3-10 Functional characterization of the A54L+V239I mutant expressed in the MMY24 S. 
cerevisae strain as constructs in the p306GPD vector. Data points are the average of three different 
experiments performed in triplicate. 
 
The A54L+V239A exhibited no constitutive activity and reduced potency 
compared to wild-type. In contrast, the A54L+V239I mutant exhibits higher 
constitutive activity than wild-type and shows a complete loss of NECA-induced 
activity. 
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3.4 Discussion 
 
3.4.1 Thermostabilisation and functional profiles 
 
The use of thermostable mutants of A2AR has been an important tool in 
facilitating the determination of high-resolution crystal structures (Lebon et al., 
2011b), but the effects of these mutations on receptor signalling function have not 
been described. The yeast cell growth assay allows simple and rapid assessment of the 
activation profile of different receptor forms. Here, the wild-type A2AR in addition to 
the previously reported Rag23, Rant5 and Rant21 mutants (Magnani et al., 2008) 
were profiled in order to obtain a greater understanding of the molecular basis of their 
thermostabilization. The results of the analysis clearly demonstrate that while Rag23 
retains high levels of agonist-induced receptor activity, the Rant mutants exhibit no 
discernable receptor activation. This is in agreement with the previous study using 
radioligand binding which showed that the Rant mutants have a significantly reduced 
affinity for the agonist NECA and a much stronger preference for the antagonist 
binding conformation than the wild-type receptor (Magnani et al., 2008). One key 
observation was the total loss of constitutive activity for all three mutant forms. 
Constitutive activity accounts for approximately 50% of the overall activity of the 
wild-type A2AR in this assay. On the basis of these data, it seems likely that the loss of 
constitutive activity observed for all three mutant receptors is a major contributory 
factor in their increased thermostability. 
Analysis of the Rant5 and intermediates revealed a clear trend in the 
characteristics of these mutants with differing degrees of reduced potency and 
reduced/no constitutive activity. One of the intermediate mutants T88A + V239A has 
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no constitutive activity and no signalling as observed for the Rant5 and Rant21 
mutants. Another intermediate mutant A54L + V239A exhibits no constitutive 
activity and much lower potency compared with the wild-type receptor. The Tm for 
this receptor form in the presence of antagonist was measured as 42°C compared to 
46°C for Rant5 and 49°C for Rant21 (Magnani et al., 2008). There is no reported Tm 
for the T88A + V239A mutant receptor but given the lack of both constitutive and 
agonist induced signalling from this construct it is likely to be similar to the Rant5 
and Rant21 mutants.  
It is clear from the data that the effects of some of the intermediate mutations 
are additive. For example the T88A mutant has no agonist-induced activity but retains 
high levels of constitutive activity while the V239A mutant has reduced potency and 
no constitutive activity. The T88A + V239A double mutant has no agonist-induced 
activity and no constitutive activity as observed for Rant5. It should be noted that the 
Rant5 does bind NECA but with much reduced affinity. The conformation change 
induced by the mutations is sufficient to prevent receptor activation but still allows 
low affinity binding of NECA. Other mutant combinations do not appear to be 
additive eg. A54L + V239A, which has the same receptor activity profile as the 
V239A only mutant. It may be that there is a benefit conferred by the A54L that is not 
detectable by this assay.  
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3.4.2 Constitutive versus agonist-induced activity 
 
The classical model of GPCR activity describes GPCRs as existing in an 
equilibrium between an active R* state and an inactive R state (Samama et al., 1993). 
This model takes into account the constitutive activity of receptors by assuming the 
transition between the inactive R to active state R* carries a sufficiently low energetic 
cost that it is possible for some receptors to be in the R* state even in the absence of 
ligand. According to this model, the increase of agonist affinity should be 
accompanied by an increase of constitutive activity. However, the data presented here 
for Rag23 and Rag23.1 shows that it is possible to have very high levels of agonist-
induced activity and ligand affinity even when constitutive activity has been 
abolished. By contrast, analysis of the T88A mutant revealed that significant 
constitutive activity was retained while the ability to be activated by NECA was lost. 
It is possible that the lack of constitutive activity observed for Rag23 and Rag23.1 is 
due to a decrease of G protein affinity for the mutated receptor. If that were the case 
the G protein would no longer be able to bind the active state of the receptor in the 
absence of ligand leading to the loss of constitutive activity. However, the presence of 
the agonist is known to increase the affinity of the G protein for the receptor and 
therefore enabling the G protein to bind the active state of the receptor to produce 
agonist-induced activity even if the overall affinity of the G protein for the receptor 
has been altered. The other possible explanation is that the agonist-induced 
conformation and the constitutive active conformation are distinct and somehow the 
mutations present in Rag23 and Rag23.1 prevent the formation of the constitutively 
active conformation without altering the agonist-induced conformation. 
In order to investigate these possibilities further, the affinity of the G protein 
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for both wild-type and Rag23.1 was investigated indirectly. The fact that the Rag23.1 
mutant exhibits maximal NECA-induced activity similar to wild-type receptor 
suggests that the loss of constitutive activity observed is not due to a reduction in G-
protein coupling. This is supported by radioligand binding analysis performed with 
[3H]NECA, which shows that the affinities of both the wild-type and Rag23.1 are 
reduced by the same amount in the absence of G-protein suggesting that the G protein 
binds both the wild-type and the Rag23.1 with a similar affinity. 
Together, these results suggest that the constitutively active and agonist-
induced active conformations of the A2AR are distinct. This is in accordance with 
previous studies that suggested a similar conclusion with the AT1 angiotensin 
receptor (Noda et al., 1996) and the β2-adrenergic receptor (Hannawacker et al., 
2002). This conclusion together with results presented by Kashai and coworkers 
showing that a GPCR is able to adopt different active conformations according to the 
agonist bound (Kahsai et al., 2011) can be summarized in an extended cubic ternary 
complex model (Fig 3-11). 
 
Figure 3-11 An extended cubic ternary complex model: the receptor is able to isomerize spontaneously 
to a constitutively active R’ state which leads to constitutive activity when bound to the G protein. 
Once bound to an agonist (A or B), the receptor adopts a ligand specific active conformation (R* or 
R”) leading to agonist-induced activity when bound to the G protein. 
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In addition, previous research on the 5-Hydroxytryptamine-4 receptor (5-
HT4R) indicates roles for a threonine residue in helix III (Thr104) and a tryptophan 
residue in helix VI (Trp272) in the formation of a so-called double toggle switch in 
stabilizing the constitutively active conformation but not the agonist-induced 
conformation of the receptor (Pellissier et al., 2009). Mutation of the Thr104 to an 
Ala leads to a dramatic decrease in constitutive activity. A comparison of the primary 
sequences indicates that Thr88 of A2AR is equivalent to Thr104 of 5-HT4R. However, 
in the case of the A2AR, mutation of Thr88 to an Ala has little effect on the 
constitutive activity but a dramatic effect on agonist-induced activity both for NECA 
and adenosine. In addition, the T88A mutation is not present in either the Rag23 or 
Rag23.1 mutants, which do not exhibit constitutive activity. Therefore, the loss of 
constitutive activity observed in the A2AR mutants must have a different mechanism 
than the one proposed for 5-HT4R. 
 
3.4.3 The role of T88 in agonist binding and receptor 
activation 
 
Previous research has shown that mutating T88A dramatically reduces both 
agonist binding and agonist-induced activity but does not significantly affect 
antagonist binding (Jiang et al., 1996). The results presented here support these earlier 
findings and show that the degree to which agonist activity is reduced is dependent on 
the agonist. NECA fails to induce any receptor activity in the T88A mutant while 
adenosine induces low but detectable activity. Binding of the two ligands shows the 
same trend. The T88A mutant shows an ~8-fold decrease in affinity for adenosine and 
a ~200 fold decrease in affinity for NECA compared with the WT receptor. Clues to 
the precise molecular basis of the difference in the responsiveness of the mutant to the 
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two agonists can be obtained from the recent A2AR structures (Lebon et al., 2011b). In 
the NECA bound structure the T88 forms a critical H-bond with the amide group of 
the ribose ring of the ligand (Fig 3-12A). In contrast the structure of the adenosine 
bound receptor reveals that the T88 is no longer able to form a H-bond with the ligand 
(Fig 3-12B). Rather this residue, together with a number of others, appears to play a 
role in stabilizing the protein via van der Waals interactions.  
 
Figure 3-12 Interaction between the Thr88 of the A2AR and NECA which is forming an hydrogen bond 
with the hydroxyl group of the Threonine (pdb: 2YDV) (A) and Adenosine which is no longer able to 
form a hydrogen bond with the hydroxyl group (pdb: 2YDO) (B) 
 
3.4.4 The role of V239 in the loss of constitutive activity 
 
The data indicate that the V239A mutation has a strong effect on constitutive 
activity. V239 is located on helix VI, pointing towards helices III and V. It is possible 
that the reduction in size of this residue by introduction of the Ala mutation allows 
helices III and VI to come into closer proximity and thus form closer interactions. 
These interactions may then prevent the movements of helices III and VI required for 
constitutive activation. Superposition of inactive A2AR structures (Fig 3-13) reveals 
that there is a 1.1 Å movement of helix III towards helix VI in an inactive 
thermostabilised mutant (containing the V239A mutation) structure (PDB: 3PWH) 
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compared with the inactive A2AR bound to an antibody (PDB: 3VG9). This shift of 
helix III towards helix VI could explain the formation of the so-called ionic lock 
between the E/DRY motif and Glu228, which is not observed in the antibody-bound 
structure. The thermostabilised mutant contains other mutations but the only other one 
susceptible to play a role in this shift is the L235A, which is likely to have a similar 
effect to the V239A. However, a potential caveat to this hypothesis is that the 
presence of the antibody may induce the differences observed between the two 
structures. 
 
Figure 3-13 Superposition of helices III and VI of the inactive thermostabilized A2AR mutant 
(containing the V239A mutation) structure (pink, Pdb accession code 3PWH) and the inactive A2AR 
bound to an antibody (blue Pdb, accession code 3VG9). The V239 or V239A and E228 residues 
located on helix VI and the R102 residue located on helix III are shown as stick models. The distance 
between the charged interacting groups of E228 and R102 of the ionic lock in each case are indicated 
by the dotted lines. 
 
In order to investigate this theory, a new mutant (A54L+V239I) was 
characterized in the yeast cell growth assay. Since the size of the residue seems to be 
a key factor, the V239 was replaced by a slightly bigger residue, an isoleucine. In 
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theory, this increase in size should keep helices III and VI further apart; facilitating 
the opening of the receptor needed for G protein binding and consequently increasing 
the constitutive activity. This is indeed what was observed (Fig 3-10) with the 
A54L+V239I mutant exhibiting a higher constitutive activity than the wild-type 
receptor. The lack of agonist-induced activity observed for this mutant remains 
unexplained. 
 
In summary, the application of the yeast cell growth assay has allowed a 
detailed analysis of the pharmacological effects of receptor mutations since it 
discriminates between constitutive and agonist induced receptor-signalling events. 
The data presented here provide strong evidence that the agonist-induced and 
constitutively active conformations of the A2AR are distinct. This information is 
complementary to, and yet distinct from, that obtained from the recent high-resolution 
structures.  In order to fully understand the mechanism of action of GPCRs it will be 
necessary to functionally and structurally characterize all the different active 
conformations. This data coupled with the high-resolution structure information may 
form the basis of rational design of receptor specific drugs that can antagonise basal 
activity with no effect on agonist-induced activity. In addition, this work suggests that 
increased receptor thermostability is correlated with the loss of constitutive activity. It 
may be that the yeast cell growth assay used in combination with either alanine-
scanning mutagenesis or random mutagenesis methods would provide a powerful 
screening tool for the production of thermostable mutants of other GPCRs. 
 
 
 
 124 
4 Functional characterization of the 
intermediate mutants between the Rag23 
and the wild-type A2AR 
 
 
 
 
 
 
The work presented here has been submitted for publication in 
PlosOne and is under review at the time of writing. 
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4.1 Introduction 
 
In the previous chapter, characterization of intermediate mutants between 
Rant5 and wild-type provided insights into the roles of individual amino acid residues 
in the function and stabilisation of the receptor. However, all the mutants explored 
were in a preferentially antagonist conformation. Functional analysis of the Rag23 
and Rag23.1 constructs suggested that the constitutively active and agonist-induced 
active conformations are distinct. Interestingly, although they comprise a completely 
different set of mutations both the Rants and the Rags exhibited no constitutive 
activity. This suggests that there are at least two different mechanisms involved in 
constitutive activity. 
Therefore in order to further investigate the differences between the agonist-
induced and the constitutive active conformations, the intermediate mutants between 
Rag23 and the wild-type were explored. In addition, the characterization of these 
intermediate mutants should provide useful data concerning the role of individual 
amino acid residues on receptor function and stabilisation as well as insight into the 
different mechanisms involved in constitutive activity. 
In this chapter, the mutants intermediate between the wild-type A2AR and 
Rag23, containing mutations (F79A, A184L, R199A, L208A and L272A) were 
explored. All possible combinations of the mutations were generated, leading to a 
total of 30 constructs, which were characterised in the yeast cell growth assay. The 
data showed that R199 and L208 have important roles in receptor function; 
substituting either of these residues for Ala abolishes constitutive activity. In addition 
the R199A mutation markedly reduces receptor potency while L208A reduces 
receptor efficacy. Furthermore, the A184L and L272A also reduce the constitutive 
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activity and the potency although to a lesser extent. In contrast, the F79A mutation 
increases constitutive activity, potency and efficacy of the receptor. These findings 
shed new light on the role individual residues have on stability of the receptor and 
also provide some clues as to the regions of the protein responsible for constitutive 
activity. Furthermore, the available adenosine A2A receptor structures have allowed us 
to put these findings into a structural context. 
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4.2 Materials and methods 
 
4.2.1 Materials 
 
Materials have already been described in chapters 2 and 3; sections 2.2.1 and 
3.2.1, respectively. 
 
4.2.2 Site-directed mutagenesis 
 
The 30 Rag intermediate mutants were obtained from the Rag23 synthetic 
gene by site-directed mutagenesis using the QuickChange Lightning Site-Directed 
mutagenesis kit and the primers detailed in Table 4-1. 
Table 4-1 Mutagenic primers used to generate the Rag intermediate mutant A2AR constructs. 
Primer Sequence (5' to 3') 
A79F_forward gatgttgggtgtttacttgcgtattttcttggctgccaga 
A79F_reverse tctggcagccaagaaaatacgcaagtaaacacccaacatc 
L184A_forward catggtctacttcaatttcttcgcgtgtgttttggtccctttgttg 
L184A_reverse caacaaagggaccaaaacacacgcgaagaaattgaagtagaccatg 
A199R_forward ctaagtccttggctattatagttggtttgttcgctttgtgttg 
A199R_reverse caacacaaagcgaacaaaccaactataatagccaaggacttag 
A208L_forward ctattttcttggctgccagaagacaactaaagcaaatggaatctcaacc 
A208L_reverse ggttgagattccatttgctttagttgtcttctggcagccaagaaaatag 
A272L_forward tcatgctccattgtggttgatgtatctagctatagttttgtcccacac 
A272L_reverse gtgtgggacaaaactatagctagatacatcaaccacaatggagcatga 
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4.2.3 Expression 
 
As described in chapter 2; section 2.2.2, all the A2AR constructs including the 
Rag intermediate mutants, were expressed as fusions with a C-terminal GFP-8His tag 
from the p306GPD vector. Estimation of the expression levels for all constructs was 
obtained from fluorescence of eGFP as previously described in chapter 3; section 
3.2.3 (Drew et al., 2008). 
 
4.2.4 Yeast cell growth assay 
 
The yeast cell growth assay was performed as described in Chapter 2; 
Section 2.2.6. 
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4.3 Results 
 
4.3.1 Expression levels 
 
Estimation of the expression levels for all the constructs using GFP gave 
values between 0.4-1.4 mg/ml (Table 4-2). The large variation observed in expression 
levels does not seem to affect the results of the assay. Indeed, Rag23.25 has the 
lowest level of expression while displaying the highest efficacy and the second 
highest level of constitutive activity. In contrast, Rag23.7 has the highest level of 
expression but exhibits no constitutive activity at all and an efficacy of only 53%. 
This suggests that the expression level is not responsible for the differences in 
efficacies and constitutive activities observed. 
Table 4-2 Expression levels of the thirty mutants and the wild-type calculated using the eGFP 
fluorescence as described by Drew et al. 
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4.3.2 F79A enhances constitutive activity and potency 
 
The activity of each of the receptor constructs is summarised in Table 4-3.  
The graphical data for all constructs is shown in Appendix 6-1. 
The effects of the F79A mutation are illustrated by the single mutant 
Rag23.30. This has increased constitutive activity and potency compared to the wild-
type while retaining similar efficacy (Figure 4-1A). These effects are also observed in 
constructs where F79A is combined with A184L and/or L272A (Rag23.13, Rag23.22 
and Rag23.25; Figure 4-1B). All these constructs exhibit wild-type or higher levels of 
potency and constitutive activity. In contrast, constructs combining F79A with R199A 
or L208A (Rag23.23 and Rag23.24; Figure 4-1B), exhibit markedly lower 
constitutive activity than the wild-type. However, the presence of the F79A mutation 
still increases the constitutive activity of the receptor compared with the equivalent 
constructs containing R199A or L208A alone (Rag23.27 and Rag23.28; Figure 4-1A). 
The same trend is also observed for receptor potency demonstrating that the effects of 
F79A on potency and constitutive activity are antagonized by the presence of the 
R199A and L208A. One exception to that is Rag23.14, the combination of F79A, 
A184L and L208A produces an overall profile similar to wild-type. It is not clear 
from either the data presented here or the receptor structures why this wild-type-like 
behaviour is seen for this construct.  
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Figure 4-1 Functional profiles of constructs illustrating the major effects of the F79A mutation. The 
F79A mutation increases constitutive activity, efficacy and potency, both alone (Rag23.30) and in 
combination with other mutations (Rag23.13, Rag23.14, Rag23.22, Rag23.23, Rag23.24, Rag23.25, 
Rag23.27, Rag23.28 and Rag23.30). The curves (A and B) are the average of two experiments 
performed in triplicate. The table (C) shows the pharmacological characteristics of each mutant 
characterized. The colours of the curves correspond to those in the table. The data for the wild-type and 
Rag23 constructs (pink) are also shown for comparison. *SEM=0 
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Interestingly, the F79A mutation is not thermostabilising but was included in 
the Rag23 because it was preferentially in an agonist-binding conformation (Magnani 
et al., 2008). The increased constitutive activity and lack of thermostabilisation of the 
F79A mutation is consistent with the previous findings demonstrating a correlation 
between loss of constitutive activity and thermostabilisation. 
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Table 4-3 Constitutive activities, potencies and efficacies of the Rag intermediate mutants. 
 
For each of the constructs shown an “x” indicates the presence of a specific mutation while a “-“ 
indicates the presence of the WT amino acid. The quadruple, triple, double and single mutants are 
indicated in the blue, yellow, green and purple sections of the table respectively. The Rag23 and WT 
receptor forms are indicated in the pink sections. The constitutive activity, potency and efficacy values 
for each receptor are shown. Each parameter is an average of two independent experiments performed 
in triplicate. *No errors are given in these examples as the data obtained from different experiments 
was so consistent as to preclude their calculation.  
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4.3.3 R199A reduces constitutive activity and potency 
 
All constructs containing the R199A mutation exhibited an almost complete 
lack of constitutive activity and reduced potency compared to the wild-type (Figure 4-
2). For clarity, Figure 4-2 only shows these effects for some examples of the 
intermediate single, double and triple mutants. However the same characteristics are 
clearly seen in all constructs with the R199A mutation (Table 4-3). The data strongly 
indicate that R199 has a key role in the constitutive activity of the A2AR. This is 
further illustrated by Rag23.24, which contains both F79A and R199A mutations. The 
profile of this mutant shows that the increase of constitutive activity due to the F79A 
mutation is almost completely overcome by the R199A mutation (Figure 4-2) and as 
mentioned above the R199A further reduces the overall constitutive activity of this 
construct compared to wild-type. The R199A also reduces receptor potency compared 
to wild-type, however the effects are less dominant than those observed for the 
constitutive activity. F79A alone increases potency but in combination with R199A 
produces a construct with wild-type potency. These findings indicate that the R199A 
cancels out the increase in potency caused by F79A but has no further effect on 
potency in this construct compared to wild-type.  
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Figure 4-2 Functional profiles of constructs illustrating the major effects of the R199A mutation. The 
R199A mutation reduces constitutive activity and potency, both alone (Rag23.28) and in combination 
with other mutations (Rag23.6, Rag23.17, Rag23.21, Rag23.24 and Rag23.28). The curves (A) are the 
average of two experiments performed in triplicate. The table (B) shows the precise details of each 
mutant characterized. The colours of the curves correspond to those in the table. The data for the wild-
type (pink) are also shown for comparison. *SEM=0 
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4.3.4 L208A mutation reduces constitutive activity and 
efficacy 
 
Almost all the constructs containing the L208A mutations exhibited very low 
or undetectable constitutive activity and markedly reduced efficacy compared with 
wild-type (Figure 4-3). As for the R199A mutation, the effect of the L208A mutation 
almost completely overcomes the enhancing effect of the F79A on constitutive 
activity, except in the presence of A184L, Rag23.14 (Figure 4-3B).  
The effects of L208A on efficacy are illustrated by the quadruple mutant, 
Rag23.1. Rag23.1 lacks the L208A substitution and has markedly increased efficacy 
compared to all the constructs containing L208A. This indicates that the low levels of 
efficacy observed in the Rag23.2, 3, 4 and 5 as well as Rag23 are due to the presence 
of the L208A mutation (Figure 4-3A). The L208A influences the potency in a similar 
way to the R199A. 
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Figure 4-3 Functional profiles of constructs illustrating the major effects of the L208A mutation. The 
L208A mutation reduces constitutive activity and efficacy, both alone (Rag23.27) and in combination 
with other mutations (Rag23.1, Rag23.2, Rag23.3, Rag23.4, Rag23.5, Rag23.10, Rag23.14, Rag23.20 
and Rag23.27). The curves are the average of two experiments performed in triplicate. The table (C) 
shows the pharmacological characteristics of each mutant characterized. The colours of the curves 
correspond to those in the table. The data for the wild-type (pink) are also shown for comparison. 
*SEM=0 
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4.3.5 The effects of A184L and L272A are overcome by the 
other mutations 
 
As can be seen from the data for the A184L single mutant construct, 
Rag23.29, this substitution has effects on the three key functional parameters assessed 
here (Figure 4-4). It reduces the constitutive activity, potency and efficacy of the 
receptor (0.%, 6.3, and 63.%, respectively; Figure 4-4B). An almost identical 
functional profile is seen for the Rag23.19 (Figure 4-4), which combines the A184L 
and L272A mutations. However, these effects are not observed in those constructs, 
which combine the A184L with L208A, R199A and/or F79A. For example, when 
A184L (Rag23.29) is combined with the strong positive effects of F79A on 
constitutive activity, potency and efficacy (Rag23.30), this leads to an increase in all 
three parameters of the resulting mutant (Rag23.25; Figure 4-4) relative to wild-type. 
In contrast, addition of A184L with R199A (Rag 23.21; Figure 4-4) or L208A 
(Rag23.20; Figure 4-4) results in reduced potency (with R199A) and efficacy (with 
L208A). 
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Figure 4-4 Functional profiles of constructs illustrating the major effects of the A184L mutation. The 
A184L mutation alone abolishes constitutive activity (Rag23.29) but this is overcome by the dominant 
effect of F79A (Rag23.25). The curves (A) are the average of two experiments performed in triplicate. 
The table (B) shows the precise details of each mutant characterized. The colours of the curves 
correspond to those in the table. The data for the wild-type (pink) are also shown for comparison. 
*SEM=0 
 
L272A alone has a moderate negative effect on the constitutive activity and 
potency of the A2AR (Rag23.26, Figure 4-5). Much like A184L, these effects are 
markedly influenced by the presence of other more dominant mutations. For example, 
when L272A is combined with F79A in Rag23.22 (Figure 4-5), this mutant still has 
increased constitutive activity and potency compared to wild-type, as a result of the 
strong influence of F79A. In contrast, when L272A is combined with R199A in 
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Rag23.17, this mutant has very low levels of constitutive activity and reduced potency 
compared to wild-type due to the influence of R199A.  
 
Figure 4-5 Functional profiles of constructs illustrating the major effects of the L272A mutation. The 
L272A mutation alone decreases constitutive activity on its own (Rag23.26) but this effect is overcome 
by the dominant effect of the F79A (Rag23.22). In the case of the combination with the R199A 
(Rag23.17) mutation there is an almost complete loss of constitutive activity. The curves (A) are the 
average of two experiments performed in triplicate. The table (B) shows the precise details of each 
mutant characterized. The colours of the curves correspond to those in the table. The data for the wild-
type (pink) are also shown for comparison. *SEM=0 
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4.4 Discussion 
 
4.4.1 Structural basis of the effects of the F79A mutation 
 
There are a number of high resolution A2AR structures which have been 
obtained using a variety of techniques and in the presence of different ligands (Dore 
et al., 2011; Hino et al., 2012; Jaakola et al., 2008; Lebon et al., 2011b; Xu et al., 
2011). Given that here the roles of mutations in a thermostabilised receptor in the 
preferentially agonist-bound conformation (Magnani et al., 2008) are explored, the 
structure of a thermostabilised A2AR containing 5 point mutations in complex with the 
agonist NECA (Lebon et al., 2011b) was used to provide further context to the results 
of this study (pdb access code: 2YVD).  
In this structure, F79 is located in helix III (Figure 4-6A and 4-6B), a region 
of the protein with key roles in GPCR function. “A consensus network of 24 inter-
helices contacts mediated by 36 topologically equivalent amino acids” has been 
identified by Venkatakrishnan and colleagues when comparing the known structures 
of GPCRs (Venkatakrishnan et al., 2013). They noted that helix III plays a major role 
in this network of contacts by interacting with all the other helices except helices I 
and VII. Therefore, helix III seems to be central for maintaining the scaffold of 
GPCRs. Furthermore, topologically equivalent residues in helix III have been shown 
to interact with the ligand in nearly all the receptors for which a high-resolution 
structure is available (Venkatakrishnan et al., 2013). Moreover, once the receptor is 
activated, helix III forms a critical interaction with the G-protein as exemplified by 
the Arg3.50 of the β2AR interacting with a backbone carbonyl of the C terminus of the 
Gs protein (Rasmussen et al., 2011a). It is therefore not a surprise that GPCR activity 
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is very sensitive to mutations in helix III, since these often lead to a complete loss of 
function or markedly increased constitutive activity (Jiang et al., 1997; Jiang et al., 
1996; Venkatakrishnan et al., 2013).  
In addition, when comparing the structure of the A2AR bound to NECA (pdb 
accession code: 2YDV) with the structure of the A2AR-T4L bound to ZM241385 (pdb 
accession code: 3EML), Lebon and colleagues observed a 2 Å upward movement of 
helix III in the active-like conformation of the receptor (Lebon et al., 2011b). In the 
inactive conformation (pdb access code: 3PWH), F79 forms van der Waals 
interactions with a number of surrounding residues including F62 and L137. These 
interactions are lost when F79 is mutated to an Ala possibly resulting in a less stable 
inactive conformation. The receptor is then more likely to adopt an active 
conformation, with the associated 2 Å upward movement of helix III, explaining the 
increase in constitutive activity observed in our study. 
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Figure 4-6 Position of the F79 (red), R199A and L208 (magenta), A184 and L272 (blue) residues in 
the high-resolution crystal structure of the A2AR GL31 thermostable mutant (2YVD) (A). F79 is 
located on helix III (B) while R199 and L208 are both located at the cytoplasmic end of helix V (C) 
and A184 and L272 are located at the extracellular end of helix V and helix VII respectively (D) The 
agonist NECA is shown in B and D. 
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4.4.2 Structural basis of the effects of the R199A and L208A 
mutations 
 
Both the R199A and L208A mutations affect constitutive activity 
dramatically. However, only the L208A mutation affects efficacy. The structures of 
the A2AR and the β2AR in complex with Gs provide clues to explain this difference. In 
the structure of the A2AR, R199 and L208 are both located in the cytoplasmic portion 
of transmembrane helix V (H V; Figure 6A and 6C). This region of helix V is 
involved in the interaction between the β2AR and the Gαs (Rasmussen et al., 2011a) 
and is thus likely to be involved in the interaction of the A2AR with the Gαi-related 
chimera protein used in the yeast cell growth assay.  
The R199 and the L208 residues are conserved in the β2 adrenergic receptor, 
corresponding to R221 and L230 respectively. Due to the lack of a structure of the 
A2AR in an active conformation, the structure of the β2 adrenergic receptor in complex 
with the Gs protein was used to aid interpretation of our data. In this structure, R221 
of the β2AR forms a hydrogen bond with a threonine (equivalent to an arginine in the 
A2AR) on helix III when the receptor is in complex with the Gs protein. This hydrogen 
bond no longer exists when R221 is mutated to an alanine. Here it was demonstrated 
that the R199A mutation completely abolishes constitutive activity of the A2AR 
without affecting efficacy suggesting that the interaction between helix III and helix 
V is crucial for constitutive activity but not for agonist-induced activity. 
The L230 residue of β2AR forms a direct interaction with the leucine at the 
extreme C-terminal end of the G protein. Mutating the equivalent residue of A2AR, 
L208, seems to prevent activation of the G protein in the absence of ligand but only 
reduces receptor activation in the presence of agonist. This suggests that this 
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interaction is crucial for formation of a constitutively active complex but it is of less 
importance in the formation of the agonist-induced active complex. 
The fact that L208 is in direct contact with the G protein whilst R199 is 
involved in making intra-receptor contacts, could explain why the L208A mutation 
has an effect on both constitutive activity and efficacy while the R199A mutation 
affects only the constitutive activity. 
 The data presented in chapter 3 suggested that the agonist induced and 
constitutively active conformations of the A2AR are distinct, thus inhibiting 
constitutive activity of the receptor does not necessarily have any negative effects on 
agonist-induced activity. 
 
Figure 4-7 Structure of the β2AR (cyan) in complex with GS protein (green) (pdb access code: 3SN6) 
viewed from the cytoplasmic face. The L230 residue of the receptor forms Van der Waals contact with 
the leucine at the extreme C-terminal end of the G protein. The R221 residue forms a hydrogen bond 
with the T136 residue on helix III 
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4.4.3 Structural Basis for the Effects of the A184L and 
L272A Mutations 
 
A184L and L272A are located on the extracellular ends of helices V and VII 
respectively (Figure 6A and 6D). Both of these residues are a significant distance 
away from both the ligand-binding pocket and the G protein-binding region. Based on 
their location in the crystal structure (Lebon et al., 2011b) these residues are unlikely 
to be directly involved in G protein coupling or ligand binding (Figure 6D). The data 
presented here, together with the available structural data, are not sufficient to explain 
why A184L and L272A have the observed functional effects in the constructs with 
these single mutations (i.e. Rag23.29 and Rag23.26). However, this does provide 
clues as to why F79A, R199A and L208A have more dominant effects on the function 
of the receptor. Interestingly, the level of the effect the mutations have on the 
pharmacological profile of the receptor is in accordance with the stabilisation effects 
of the individual mutations observed by Magnani and colleagues when they generated 
these mutants. One exception is the F79A mutation, which is not thermostabilising 
(Magnani et al., 2008). For example, the R199A (Rag23.28) and L208A (Rag23.27) 
single mutants retain 101% and 108% of the wild-type binding activity after heating 
at 30°C for 30 minutes respectively while the A184L (Rag23.29) and L272A 
(Rag23.26) retained 75% and 79% respectively. In this analysis, wild-type binding 
activity after heating is 50%. The F79A mutant shows similar levels of activity after 
heating as the wild-type receptor. 
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In conclusion, the R199A and L208A mutations inhibit constitutive activity 
of the A2AR receptor while F79A enhances constitutive activity. In addition, the 
L208A mutation also affects the efficacy of the receptor. The effects of A184L and 
L272A are overcome by the more dominant F79A, R199A and L208A mutations. 
Analysis of the mutations alone and in combination using the yeast assay, together 
with the known A2AR structures provides information on the role of individual amino 
acids in receptor function. However as with all types of analysis of this kind, it can be 
difficult to fully dissect the activity of an individual amino acid from the contributions 
of all others. A full understanding of the roles of all the amino acid residues will only 
be revealed through multiple crystal structures in a range of different conformations 
coupled with detailed dynamics studies. 
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5 Discussion and future outlook 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
GPCRs are essential integral membrane proteins that respond to a wide range 
of stimuli such as hormones, peptides and neurotransmitters. As such they are the 
targets of many modern drugs. For many years, our understanding of GPCR 
mechanism of action was limited by the lack of high-resolution structural information. 
This was due to several reasons including the difficulties in expressing the protein of 
interest in quantities large enough for structural studies (Andre et al., 2006; 
Grisshammer, 2006; McCusker et al., 2007; Sarramegna et al., 2003), the highly 
dynamic nature of GPCRs (Kobilka & Deupi, 2007), which makes them difficult to 
isolate in a relevant conformation, and finally their low propensity to crystallize 
(Rosenbaum et al., 2007). However, recent progress in the field of GPCR 
overexpression, stabilization and crystallization has resulted in the publication of 58 
high-resolution structures of 22 different GPCRs, excluding Rhodopsin, in the last 
few years. These are essential to furthering our understanding of GPCR function and 
to facilitate drug design. However, these structures are of highly engineered receptors 
and little is known about the effect these modifications have on receptor signalling 
function. One successful method for GPCR structure determination is the introduction 
of thermostabilising mutations through alanine scanning mutagenesis. Through this 
method, it is possible to isolate receptors in either a preferentially agonist-binding or 
antagonist-binding conformation. This reduces the conformational flexibility of the 
receptor, resulting in increased thermostability. Investigation of the signalling 
properties of several thermostable mutants of the A2AR using a functional yeast assay 
revealed several important findings. 
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5.1 Agonist-induced and constitutive active 
conformations are distinct 
 
The results from our studies showed that Rag23 and Rag23.1, both of which 
are in agonist-binding conformations, exhibit increased potencies and affinities for 
NECA compared with the wild-type while displaying a complete loss of constitutive 
activity. These findings are not explained by the extended ternary complex model 
(Samama et al., 1993). Further investigation revealed that the interaction between the 
receptor and its G protein has not been altered by the mutations in Rag23.1. A 
possible explanation to these observations could be that the agonist-induced and 
constitutive active conformations are distinct. Pellisier and coworkers showed that 
different conformational rearrangements occur during the stabilization of the active 
states of the 5-HT4 receptor according to the agonist used. In addition, they also 
showed that different residues were involved in the formation of constitutive and 
agonist-induced active conformations, reinforcing the idea of distinct conformations 
(Pellissier et al., 2009).  
These findings have major implications for drug design, since it may be 
possible to design allosteric drugs that would block unwanted constitutive activity of 
a specific receptor without having any effect of receptor activation through 
endogenous ligands. This could dramatically reduce side effects since it would allow 
the receptor to function normally upon release of endogenous ligand. 
 
 
 
 
 151 
5.2 Role of individual residues in receptor function 
and stabilisation 
 
The analysis of the mutants intermediate between Rag23 and the wild-type 
and between Rant5 and the wild-type revealed the role of individual residues in 
receptor function and stabilisation. In that regard, the yeast functional assay provides 
a powerful tool in combination with high-resolution structures, since it is difficult to 
identify the role of individual residues on receptor function and stabilisation using 
high-resolution structural information alone. 
 
5.2.1 T88 plays a crucial role for agonist-induced activity 
 
The results presented here are in accordance with previous findings showing 
that Thr88 plays a crucial role in ligand binding and in agonist-induced activity (Jiang 
et al., 1997) of the A2AR. In addition, the data show that this effect is agonist-
dependant. Indeed, while NECA is no longer able to activate the T88A mutant, 
adenosine still activates T88A with a reduced potency. This T88 residue (3.36 in the 
Ballestros-Weinstein numbering) seems to be important in most GPCRs, as it is part 
of the “ligand-binding cradle” described earlier. However, the effect of mutating this 
residue is receptor specific. Indeed, replacing S3.36 in the H1 receptor by a threonine 
dramatically increased the constitutive activity while replacing it with an alanine 
completely abolishes it (Jongejan et al., 2005). In addition, replacing T3.36 in the 5-
HT4R with an alanine also abolishes constitutive activity (Pellissier et al., 2009). 
Therefore it is obvious that the 3.36 residue plays a crucial role across GPCRs either 
on the ligand-binding properties or on the constitutive activity. 
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5.2.2 Role of individual residues on constitutive activity 
 
The functional characterisation of the intermediate mutants revealed that 
there are several mechanisms to block constitutive activity, highlighting the 
complexity of receptor activation. Indeed, the reduction in size of the residue when 
mutating V239 to an alanine, seems to bring helices III and VI closer to each other, 
strengthening their interaction and blocking the outward movement of helix VI 
needed for GPCR activation. 
The loss of constitutive activity observed in the R199A mutant involves a 
different mechanism. It is possible to speculate about the mechanism involved in the 
loss of constitutive activity by looking at the structures of the A2AR in an inactive 
conformation, in a partially active conformation and the structure of the β2AR in 
complex with Gs. However, it is important to bear in mind that the structures of the 
partially active A2AR and the active β2AR are in agonist-induced conformations, 
which limits interpretation of why the R199A mutation abolishes constitutive activity. 
In the structure of the A2AR in an inactive conformation, R199 does not seem to be 
interacting with any other residues within the receptor and is 4.6 Å away from R107 
located on helix III (Fig 5-1A). However, the structure of this receptor bound to an 
agonist and in a partially active conformation reveals that R199 is now 3.9 Å away 
from R107 (Fig 5-1B). In the β2AR structure, T136 (equivalent to A2AR R107) forms 
a hydrogen bond with R221, (equivalent to A2AR R199) (Fig 5-1C). Therefore, it 
seems that upon activation of the receptor, the movement of helices III and V brings 
R107 and R199 in close proximity, stabilising the active conformation. Clearly, this 
interaction is not crucial for the stabilisation of the agonist-induced active 
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conformation but is necessary for the stabilisation of the constitutive active 
conformation. 
 
 
Figure 5-1 Position of the R199 residue of the A2AR or its equivalent R221 of the β2AR in an inactive 
conformation (A), in a partially active conformation (B) and in a fully active conformation (C), looking 
down from the extracellular face. 
 
Finally, the L208 residue, equivalent to L230 in the β2AR, is involved in 
both constitutive activity and efficacy. This is certainly due to the direct interaction of 
this residue with the C-terminal tail for the Gs protein in the β2AR structure in 
complex with Gs. However, mutating this residue to an alanine completely abolishes 
constitutive activity while it only partially reduces efficacy. It is possible that when an 
agonist is bound to the receptor extra stabilising interactions, not occurring in the 
constitutively active conformation, allow the formation of an active complex between 
the receptor and the G protein which involves residues other than L208. 
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5.3 The yeast functional assay as a screening tool 
 
The data presented here demonstrates that there is a correlation between 
thermostability and loss of constitutive activity. In addition, this assay allows the 
distinction between agonist-binding and antagonist-binding conformations. This 
means that this yeast functional assay could be used to screen stable mutants that 
would preferentially be in an active or inactive conformation. Indeed, this assay is 
high throughput, inexpensive and has been demonstrated to work with other GPCRs 
such as the cannabinoid CB1 and CB2 receptors (Dowell & Brown, 2009), GPR41 and 
GPR43 (Brown et al., 2003) in addition to the A2AR reported here, demonstrating the 
broad applicability of this method. This method would also offer the advantage of 
knowing that the stable construct generated is in a functionally relevant conformation.  
Furthermore, previous studies on other GPCRs gave no evidence that the 
pharmacology in yeast is ‘wrong’ compared with mammalian cell systems, based on 
such criteria as rank orders of potency of ligands and the translation of compound 
activities into more complex systems. Indeed, in many cases, yeast data have been 
more predictive of phenotypic or in vivo studies than data from recombinant 
mammalian cell assays (GSK unpublished data). This highlights the relevance of 
using the yeast system as a screening tool. 
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5.4 Future outlook 
 
Although, the yeast functional assay provides useful data on GPCRs function 
and stabilisation, it has limitations. Indeed, while this assay provides information on 
the role of individual residues on the function of receptor, it is difficult to identify the 
mechanisms underlying this effect without a high-resolution structure. In order to 
fully understand the complexity of the activation mechanism of GPCRs, high-
resolution structures of native receptors in all the different conformations and bound 
to β-arrestin as well as G protein would be needed.  
Another limitation of this assay that it shares with crystal structures of 
GPCRs, is that it is impossible to investigate the dynamics of the receptor in their 
native environment. This can be achieved by using solid-state NMR technique since 
NMR can describe both overall and local protein dynamics. In addition, structures of 
unmodified receptors can be obtained in phospholipids bilayer, as demonstrated by 
the structure of the CXCR1 chemokine receptor (Park et al., 2012). Furthermore, 
NMR technique was used to study the dynamics of the β2AR by labelling strategically 
positioned methionines (Nygaard et al., 2013). Nygaard and co-workers were able to 
observe an alternative inactive state that slowly exchanges with the 
crystallographically observed inactive state in the absence of ligand or upon inverse 
agonist binding. They also demonstrated that upon agonist binding the receptor is 
structurally heterogeneous and that the most populated conformation is distinct from 
the inactive states. Finally, when the receptor is bound to both an agonist and the 
Nb80 nanobody, which mimics the G protein, the receptor adopts a more 
homogeneous conformation corresponding to the fully active state, different from the 
intermediate active states observed upon agonist binding only. 
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It seems that only a combination of biochemical studies, X-ray 
crystallography and NMR spectroscopy will allow researchers to fully understand the 
dynamics and detailed mechanism of action of GPCRs. 
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6 Appendix 
 
6.1 Graphical data for all the Rag23 intermediate 
mutants 
 
NECA-induced activity of the WT A2AR, Rag23 and the quadruple mutants intermediate between the 
WT and Rag23. See Table 4-3 for the precise details of each mutant. The receptor constructs were 
expressed in the MMY24 S. cerevisiae strain using the p306GPD vector. The activity of cells 
containing empty vector is shown as a control. 
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NECA-induced activity of the WT A2AR and the triple mutants intermediate between the WT and 
Rag23. See Table 4-3 for the precise details of each mutant. The receptor constructs were expressed in 
the MMY24 S. cerevisiae strain using the p306GPD vector. The activity of cells containing empty 
vector is shown as a control. 
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NECA-induced activity of the WT A2AR and the double mutants intermediate between the WT and 
Rag23. See Table 4-3 for the precise details of each mutant. The receptor constructs were expressed in 
the MMY24 S. cerevisiae strain using the p306GPD vector. The activity of cells containing empty 
vector is shown as a control. 
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NECA-induced activity of the WT A2AR and the single mutants intermediate between the WT and 
Rag23. See Table 4-3 for the precise details of each mutant. The receptor constructs were expressed in 
the MMY24 S. cerevisiae strain using the p306GPD vector. The activity of cells containing empty 
vector is shown as a control. 
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6.2 Permission to republish third party 
copyrighted work from chapter 3 
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6.3 Yeast transformation protocol 
 
1. Pick a single yeast colony and grow in 5mls medium overnight (shaking at 30oC) 
which should give a saturated culture (approx. 1x108 cells/ml). 
2. Next morning, make a 1/100 dilution into 100mls and grow for 4-8 hours (approx. 
2-3 generations; final density approx. 1x107 cells/ml). 
3. Spin at 4000 r.p.m. for 1 min. to harvest. 
4. Wash in sterile water, and reharvest. 
5. Resuspend cells in 1ml LiAc-TE (approx. 1x109 cells/ml). 
6. Take 50ml cells per transformation, and add 5ml ssDNA. 
7. Add 1mg DNA to be transformed. 
8. Add 300ml LiAc/PEG/TE and mix. 
9. Incubate either at R.T. or 30oC with occasional (or gentle) agitation for 10 min. 
10. Heat shock in 42oC water bath for 20 min. 
11. Remove, and plate 50ml directly onto selective plates.  
The method is so efficient, you don’t need to plate out the whole transformation onto 
a small petri dish.  
12. For chromosomal integrations, use ~5 ug DNA and linearize in the selectable 
marker gene (using eg. NsiI or StuI for URA3); you may need to plate out all the 
transformation mixture as the efficiency is lower than for episomal plasmids.  
Solutions 
Make up:  1) 1M LiAc 
  2) 50% PEG3350 
  3) 10xTE pH7.5 (0.1M Tris-Cl pH7.5, 0.01M EDTA) 
LiAcTE  is 5mls 1M LiAc, 5mls 10xTE, 40mls H2O  
LiPEG-TE is 5mls 1M LiAc, 5mls 10xTE, 40mls 50% PEG 
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ssDNA Sigma D-9156 Salmon Testes DNA aliquoted into microfuge tubes, 
  boiled for 10 min, cooled immediately in ice and frozen (for best  
  efficiency, don’t use aliquots more than twice).  
 
